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Thrombocytopenia and the most severe form of coagulation disturbance, 
disseminated intravascular coagulation (DIC), are both frequent findings in critically 
ill patients and especially in those with severe sepsis. Patients with coagulation 
disturbance develop more organ dysfunction and have higher mortality. The 
pathophysiology behind the increased morbidity and mortality remains unclear.  
The focus of this thesis was on assessing the applicability of diagnostic tools for 
DIC: a modification of a score suggested by the International Society on Thrombosis 
and Haemostasis (ISTH), and thromboelastometry (TEM), a whole-blood 
viscoelastic coagulation monitor. A further aim was to evaluate matrix 
metalloproteinase-8 (MMP-8), tissue inhibitor of metalloproteinase-1 (TIMP-1), 
nucleosomal histone-complexed DNA (hcDNA) and high-mobility group box 1  
(HMGB1) protein levels in patients with and without DIC or thrombocytopenia and to 
assess their association with organ dysfunctions and outcome.  
 
Patients and methods 
Studies I-IV comprised 769 patients. Study I was a retrospective cohort study. All 
patients admitted to the multidisciplinary intensive care unit (ICU) of Helsinki 
University Hospital between 1.1.2002 and 31.10.2003 were screened for intensive 
care diagnoses. A modified score for overt DIC based on daily laboratory routines 
was calculated on days 1 to 7 or until discharge if that occurred earlier, and daily 
antithrombin was recorded, if available. 
Study II was a prospective pilot study that included 28 patients with severe sepsis at 
admission. Diagnosis of overt DIC was based on daily calculations of modified DIC 
score. Ten healthy persons served as controls. TEM analyses using two different 
ROTEM® tests, EXTEM and FIBTEM, were performed on day 1 immediately after 
admission to ICU.  
Study III was a prospective pilot study that contained 22 patients with severe sepsis 
at the time of admission or within 48 hours prior to admission. Serum MMP-8 and 
TIMP-1 concentrations were measured by time-resolved immunofluorometric and 
enzyme-linked immunosorbent assays (ELISA) at admission, and on days 2, 4 and 
7, simultaneously with traditional coagulation assays and fibrin formation markers.  
Study IV was a sub-study of the FINNAKI study, a large, prospective, observational, 
multicentre study conducted in 17 Finnish ICUs over a five-month period. Of the 918 
patients with severe sepsis at admission or within the first 24 hours in the ICU, we 
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included a sub-cohort of 225 consecutive patients with admission plasma sample 
available for analyses. Admission levels of hcDNA and HMGB1 were analysed by 
commercial ELISA assays. The kinetic analysis comprised 49 patients for whom 
hcDNA and HMGB1 were measured at 0, 24 and 48 hours.  
 
Main results 
The incidence of DIC ranged from 31% in unselected ICU patients with appropriate 
underlying disease (I) to 41% (III) and 43% (II) in patients with severe sepsis. In 
Study IV, 33% of the patients developed thrombocytopenia, with platelet count <100 
x109 /litre.  
In DIC, 28-day mortality ranged from 40% to 44% (I-III); in patients with 
thrombocytopenia 90-day mortality was 39% (IV).  
Study I demonstrated that of the components in the modified ISTH score, platelets, 
prothrombin time (PT) ratio and D-dimer either excellently or well, and fibrinogen 
only poorly discriminated the patients with overt DIC by receiver operating 
characteristics (ROC) curve analysis. Antithrombin possessed good discriminative 
power, comparable to PT ratio and D-dimer. DIC diagnosis based on the score was 
not an independent predictor of 28-day mortality.  
In Study II, traditional coagulation tests showed a consistently worsening 
coagulopathy from healthy controls to patients without DIC and those with DIC. TEM 
analysis revealed that in patients with DIC clot formation time (CFT) was prolonged 
and maximal clot firmness (MCF) was decreased relative to both patients without 
DIC and healthy controls, indicating hypocoagulation. Patients without DIC had a 
similar TEM profile to controls, except that MCF showed a trend for 
hypercoagulation. In all patients, fibrinolysis was inhibited. EXTEM CFT, α-angle 
and MCF discriminated patients with DIC well.  
Study III showed that MMP-8 and TIMP-1 concentrations were elevated in severe 
sepsis. MMP-8 was higher on day 2 in DIC patients than in patients without DIC. 
TIMP-1 was higher on days 1 and 2. TIMP-1 correlated negatively with platelet 
count, several coagulation parameters and disease severity scores.  
In Study IV, hcDNA and HMGB1 levels were elevated in patients with 
thrombocytopenia or acute kidney injury (AKI) and in those who died within 90 days. 
HcDNA independently predicted thrombocytopenia, whereas HMGB1 was a 
predictor of the severest stage of AKI and of 90-day mortality.  
 
Conclusions  
In the university hospital multidisciplinary ICU, incidence of DIC was 31% in 
unselected patients with appropriate underlying diagnosis and over 40% in those 
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with severe sepsis. A prospective multicentre cohort study revealed a lower 
incidence (33%) of thrombocytopenia in severe sepsis patients. Components of the 
modified score for overt DIC discriminated patients with DIC well, except that 
fibrinogen proved useless. Discriminative power of AT was comparable to D-dimer 
and PT ratio. TEM analysis revealed that patients with DIC had hypocoagulable 
TEM trace as compared with sepsis patients without DIC. Clot strength and clot 
formation parameters discriminated DIC patients well from those without DIC. The 
markers speculated to contribute to coagulation disturbance and organ dysfunction, 
MMP-8, TIMP-1, hcDNA and HMGB1, were higher in patients with disturbed 
coagulation. HcDNA and HMGB1 were also elevated in patients with AKI and 
adverse outcome. HcDNA was an independent predictor of thrombocytopenia.  
 
Keywords 
Disseminated intravascular coagulation, severe sepsis, organ dysfunction, mortality, 
thrombocytopenia, thromboelastometry, matrix metalloproteinase-8, tissue inhibitor 
of metalloproteinase-1, nucleosomes, high-mobility group box 1  
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1. INTRODUCTION 
Critically ill patients, regardless of their underlying disease, are prone to blood 
coagulation disorders. Several factors, including chronic illnesses, disturbed 
homeostasis, acquired platelet dysfunction, minor and major surgical procedures, 
immobilization, vascular catheters, extracorporeal circuits and medications, 
predispose to both bleeding and thrombotic complications.1 In the intensive care unit 
(ICU), approximately 40% of the patients develop thrombocytopenia (defined as 
platelet count <150 x109 /litre),2,3 and an international normalized ratio (INR) is 
increased in 30%.4 Disturbed coagulation and its consequences may lead to organ 
dysfunction, prolonged hospitalization and increased mortality.  
Severe sepsis is a common life-threatening condition in which an infectious agent 
triggers a series of proinflammatory reactions that manifest as haemodynamic 
imbalance, organ dysfunction and almost universal signs of coagulation 
abnormalities.5 In addition to careful monitoring and customized medication, these 
patients are often administered excessive fluid therapy, ventilator support and renal 
replacement therapy (RRT) because of manifestations of organ dysfunction.  
The most severe form of coagulation disturbance is disseminated intravascular 
coagulation (DIC), which may occur in several critical conditions, including 
inflammatory diseases, such as severe sepsis, trauma, organ destruction (e.g. 
pancreatitis) and obstetric emergencies. In DIC, intravascular coagulation is 
activated without macroscopic vessel injury, which leads to thrombocytopenia and 
consumption of coagulation factors. In addition, inactivation of the natural 
anticoagulant system and inhibition of fibrinolysis may occur, rendering the patients 
susceptible to both bleeding and thrombosis. Microvascular fibrin deposition and 
thrombosis occurring in DIC are thought to contribute to the development of multiple 
organ dysfunction and to increase mortality, although the mechanisms have been 
under debate.6  
To standardize and facilitate the diagnosis of DIC, the International Society on 
Thrombosis and Haemostasis (ISTH) has proposed criteria and a score for overt 
DIC based on easily available global coagulation assays.7 Several studies have 
proven the ISTH score applicable in early recognition of DIC, but milder coagulation 
disturbance still lacks proper diagnostic criteria, despite an apparent association with 
increased mortality.8-10 From the clinical point of view, these patients are not prone 
to bleeding, contrary to what traditional coagulation assays may suggest.  To date, 
no widely accepted treatment for severe sepsis-associated DIC exists.  
The pathophysiology behind the development of sepsis-related organ dysfunction 
and failure is very complex. Suggested mechanisms include exaggerated 
interactions between numerous inflammatory mediators and regulators, cell-cell 
interaction molecules, cell apoptosis and excessive activation of coagulation.11 
Endothelial dysfunction seems to be a key step, however, little is known about the 
exact mechanisms or differences in susceptibility of organs.  
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The main focus of this thesis was to assess incidence of DIC with a score suggested 
by ISTH in ICU patients with appropriate underlying diseases known to be 
associated with DIC, and to evaluate blood coagulation in severe sepsis with a 
viscoelastic method, thromboelastometry. Another focus was on the 
pathophysiology of sepsis-related coagulation disturbance: separate studies 
investigated the roles of extracellular matrix-degrading proteins and their inhibitory 
enzyme, and circulating nucleus-derived proteins in the development of 






2. REVIEW OF THE LITERATURE 
2.1 HAEMOSTASIS IN VASCULAR DAMAGE 
Haemostasis is a normal physiological process that causes blood to clot at a site of 
vascular injury. In primary haemostasis, activated platelets adhere to the site of 
damage and aggregate, forming a primary clot. This provokes a series of reactions, 
which finally form a tight fibrin network between aggregated platelets. 
2.1.1 Platelets and primary haemostasis 
Platelets are small anucleate cells that are fragments of the membrane, cytoplasmic 
organelles and granules of megakaryocytes and are composed in bone marrow. 
After release into the blood, platelets circulate for 7-10 days before being 
phagocytized by the spleen or the liver. Inactivated platelets circulate as discoid 
plates.12  
The primary function of platelets is to maintain vascular integrity. When the vascular 
wall is injured for any reason, circulating platelets interact with exposed material, 
adhere to the site of injury and become activated. Upon activation, the cytoskeleton 
of the platelet rapidly rearranges, and platelets spread and form thin sheets 
(lamellae) and long thin processes (filopodia).12 In this form, platelets start to form an 
initial plug to stop the bleeding and correct the damage.  
Platelets interact with other cells, extracellular matrix and soluble compounds by 
several groups of membrane receptors. Interaction facilitates activation, adhesion 
and aggregation phases. Thrombin, a major mediator of the coagulation process, 
binds to protease-activated receptors (PARs), the main one being PAR-1. PAR-1 
mediates platelet activation and amplifies the coagulation process.13 At the site of 
injury, platelets adhere to exposed collagen by integrin-type receptors, especially 
glycoprotein (GP) Ib/V/IX, VI and Ia/IIa. Von Willebrand factor (vWF), on the surface 
of exposed collagen, serves as a major ligand for GP Ib. This receptor-vWF 
interaction reduces the velocity of platelets in blood vessels and allows them to 
attach to the site of injury. Platelet aggregation occurs mainly by the most abundant 
integrin, GP IIa/IIIb, which binds to fibrinogen, fibrin and other ligands, promoting 
aggregation of platelets.13,14 
Activated platelets secrete numerous compounds from their α granules, dense 
granules, lysosomes and cytoplasmic stores, all contributing to platelet adhesion, 
aggregation and modulation of endothelial function and inflammatory processes. 
Nowadays, platelets are considered vital to host immunity.15 
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2.1.2 Coagulation process 
Historically, blood coagulation has been seen as a sequential process in which 
coagulation factors first become activated and then activate the following factors in 
predefined order.16,17 The waterfall cascade model included both intrinsic and 
extrinsic pathways, which were thought to unite at the level of factor X (FX) and form 
a final common pathway. The main reaction in the coagulation process is the 
formation of thrombin, which digests fibrinogen into fibrin, the main constituent of a 
blood clot.  
After the introduction of the cascade model, it was soon realized that it could not 
explain all of the phenomena seen in patients with congenital coagulation factor 
deficiencies. Moreover, a well-functioning extrinsic pathway was unable to 
compensate defects on the intrinsic pathway and vice versa. Several factors were 
found to interact, irrespective of their order in the cascade.18  
Nowadays, activation of coagulation is thought to occur mainly on cell surfaces, and 
cells control the process actively. Instead of a mechanical cascade model, 
coagulation occurs as overlapping phases on different cell surfaces.19-21 
Initiation phase: Tissue factor (TF), a specific cell surface molecule, is exposed to 
circulating blood either by endothelial injury or inflammation. TF activates factor VII 
(FVII) and, as a consequence, FX becomes activated and produces thrombin in 
small amounts. 
Amplification phase: Blood components, platelets, vWF and factor VIII (FVIII) 
come into contact with small amounts of thrombin on TF-bearing cells. Thrombin 
fully activates platelets as well as a number of coagulation factors, factors V, VII and 
XI. 
Propagation phase: The reaction greatly amplifies. Factor IX combines with 
activated FVIII and activates FX to FXa, which combined with activated FV (FVa) 
converts large amounts of prothrombin to thrombin. As a result, fibrinogen is cleaved 
to fibrin monomers, which polymerize and in the presence of activated factor XIII 
form a stabilized fibrin mesh and a thrombus with initial platelet clot. 
2.1.3 Regulation of coagulation  
Natural anticoagulant mechanisms control fibrin formation tightly to keep the process 
localized. Tissue factor pathway inhibitor (TFPI) is the major regulator of the 
initiation phase, whereas antithrombin (AT) and activated protein C (aPC) inhibit 
thrombin formation in the propagation phase.20 TFPI forms a complex with activated 
FVII (FVIIa) and FXa, thereby directly inhibiting the early phase of the coagulation 
process.22 AT directly inhibits formed thrombin and other serine proteases.23 
Thrombin also binds to endothelial thrombomodulin, and this complex activates 
protein C. APC, with the contribution of protein S, cleaves factors VIIIa and Va and 
thereby inhibits propagation of coagulation.24 In addition, platelets contain a large 
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variety of receptors and other signalling proteins that have a role in the regulation of 
thrombin formation and clot retraction.25  
2.1.4 Fibrinolysis 
Fibrinolysis is a sequence of enzymatic reactions, which start to degrade fibrin into 
soluble fibrin degradation products. The final aim is to remove the blood clot from 
the vessel wall as the epithelium heals, but fibrinolysis also regulates clot formation 
and keeps it localized.  
Plasminogen is an inactive pro-enzyme that becomes activated to plasmin in the 
presence of fibrin by tissue- and urokinase-type plasminogen activators (t-PA and u-
PA). Plasmin degrades fibrin network to degradation products, e.g. D-dimer, which 
can be measured.26  
Several enzymes regulate fibrinolysis. Alpha-2-antiplasmin is the major inhibitor of 
plasmin. Plasminogen activator inhibitor-1 (PAI-1) inhibits both t-PA and u-PA, and it 
also plays a role in cell adhesion and migration.27 Thrombin-activatable fibrinolysis 
inhibitor prevents binding of plasminogen to fibrin, thereby suppressing fibrinolysis.28 
2.2 DISTURBED COAGULATION IN THE CRITICALLY ILL 
Critically ill patients are susceptible to many coagulation disturbances. Patients may 
have multiple traumas and organ destructions, causing massive bleeding. Acute 
critical illness and many underlying diseases may activate the coagulation process 
without observable tissue injury. Many ICU-related factors, such as catheterizations, 
extracorporeal circuits, immobilization and certain drugs, predispose patients to 
either bleeding or thrombotic complications, or both. Often a patient may be prone to 
thrombosis and bleeding at the same time.29,30 
2.2.1 Thrombocytopenia 
Thrombocytopenia is a frequent finding in unselected critically ill patients. The 
definition of thrombocytopenia varies, but in general, platelet count below 150 x109 /l 
is considered mild, 50-99 x109 /l intermediate and <50 x109 /l severe 
thrombocytopenia. According to a recent systematic review, the prevalence of 
thrombocytopenia on admission to the ICU ranged greatly, from 8% to 68%, and the 
incidence during the course of ICU from 13% to 44% depending on the patient 
population.31  
Thrombocytopenia is often multifactorial in origin. It may occur due to massive 
consumption (bleeding, disseminated intravascular coagulation or other thrombotic 
thrombocytopenic disorders), immune-mediated destruction, decreased production 
(toxic effects or viral infections), platelet sequestration to the spleen (liver and heart 
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diseases and haematological disorders), or a combination of these.32,33 In the ICU 
setting, sepsis is one of the leading causes of thrombocytopenia, which occurs in 
over 50% of patients with septic shock.34 Other causes are commonly used 
medications (piperacillin-tazobactam and other β-lactams, vancomycin, linezolid and 
heparin), especially after prolonged administration, and induced hypothermia.35 
Thrombocytopenia predicts poor prognosis, is associated with bleeding 
complications and may delay important procedures. Several studies have shown 
that both thrombocytopenia per se and reduction in platelet count are independent 
predictors of death.3,32,36,37 Patients with platelet count <50 x109 /l have a 3- to 5-fold 
risk of bleeding relative to those with a higher platelet count.32,33,38,39 
2.2.2 Coagulation in severe sepsis 
Severe sepsis is an overwhelming systemic inflammatory response to an infectious 
agent complicated by one or more acute organ failures. Septic shock is defined as 
hypotension refractory to adequate fluid resuscitation, and signs of insufficient 
perfusion.40,41 Incidence of severe sepsis ranges from 0.48 to 3.0/1000/year.42-45 
Despite advancements in modern intensive care, mortality remains high, from 23% 
to >60% in those with at least four concomitant organ failures.43,46,47  
Coagulation is activated in virtually all patients with a systemic inflammatory 
reaction. Inflammatory mediators, cytokines, chemokines and the complement 
system activate the endothelium and convert it into a prothrombotic surface. It has 
become clear that coagulation and inflammation are in tight crosstalk and strongly 
modulate each other.11,48 Figure 1 demonstrates a simplified representation of 
coagulation activation in inflammatory reactions.   
 
1) Activation of coagulation  
In severe sepsis, TF has an essential role in initiation of coagulation. 
Cytokines, C-reactive protein and other inflammatory agents induce 
expression of TF on the surface of the endothelium and circulating 
monocytes, macrophages and microparticles, enucleated fragments from 
activated and apoptotic cells.  This induction occurs in the presence of 
platelets and granulocytes and results in activation of the coagulation 
process, and finally, formation of thrombin.  
2) Inhibition of natural anticoagulant mechanisms  
a. Proinflammatory cytokines may impair the attachment of TFPI 
on the endothelial surface, thereby reducing its function. 
b. AT activity is markedly reduced because of impaired synthesis, 
increased degradation and consumption due to binding to 
excessive amounts of thrombin. 
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c. The liver produces less PC. In addition, TM expression on the 
endothelium is down-regulated, and endothelium-bound TM is 
cleaved and released to the circulation. Soluble TM is much 
less active than endothelium-bound TM. As PC activation 
normally requires the presence of TM-bound thrombin, 
endothelial protein C receptor (EPCR) and co-factor protein S, 
these alterations inevitably reduce PC activation and 
anticoagulant capacity. 
3) Supressed fibrinolysis  
In sepsis, fibrinolysis-inhibiting enzyme PAI-1 levels increase in response to 
circulating tumour necrosis factor alpha (TNF-α) and interleukin-1β.49 As a 
consequence, inadequate fibrin removal may lead to microvascular 
thrombosis. 
4) Coagulation-inflammation interaction  
Coagulation modulates inflammation by several mechanisms. PARs are 
receptors located on the surface of endothelium, monocytes, platelets and 
fibroblasts. Thrombin, TF/FVIIa-complex and FXa can activate PARs to 
produce inflammatory cytokines and growth factors.50 
Activated platelets strongly contribute to host immunity by secreting and 
releasing many inflammatory mediators and interacting with most 
leukocytes. Activated and aggregated platelets may capture neutrophils and 
bring them in close contact with the disrupted endothelium.15,51 
AT possesses potent anti-inflammatory properties. AT induces prostacyclin 
release, which, in turn, inhibits platelet activation and aggregation and 
decreases production of various proinflammatory agents. AT also directly 
blocks the interaction of leukocytes with endothelial cells.48  
Anti-inflammatory effects of aPC are mainly mediated by EPCR. APC 
inhibits production of proinflammatory cytokines, inhibits leukocyte 
chemotaxis and adhesion, protects against disruption of endothelium and 
prevents endothelial apoptosis.52  
Many fibrinolytic factors, in particular u-PA and its receptor u-PAR, mediate 
leukocyte adhesion and migration.53 Potential mediators in this process are 
extracellular matrix-degrading proteases (plasmin and metalloproteinases), 
which are activated by u-PA and u-PAR.54 PAI-1, instead, may inhibit this 





Figure 1. Simplified presentation of coagulation disturbance in severe sepsis. 
In severe systemic inflammatory reaction, a large number of mediators, including 
cytokines, chemokines and components of the complement system, initiate an 
exaggerated activation of platelets and the coagulation system and the simultaneous 
inhibition of fibrinolysis.  These compounds further activate the endothelium, which 
starts to express tissue factor (TF, red triangle). TF is also released to the circulation 
from other tissues by disruption of endothelial integrity. TF initiates series of 
enzymatic reactions, which lead to a thrombin ‘burst’.  The end-product of the 
coagulation process, fibrin, forms clots with activated and aggregated platelets on 
the surface of the activated endothelium. Apoptotic endothelial cells release 
intranuclear compounds, e.g. histones and high-mobility group box 1 (HMGB1) 
protein, which enhance both inflammation and coagulation reactions either directly 
or by neutrophil extracellular traps (NETs). Reduced amount of natural 
anticoagulants cannot suppress these reactions, and microvascular thrombosis may 
occur.  
AT, antithrombin; aPC, activated protein C; EPCR, endothelial protein C receptor; FVIIa, 
activated FVII; FX, factor X; FXa, activated factor X; PC, protein C; PS, protein S; TM, 
thrombomodulin; TFPI, tissue factor pathway inhibitor.  
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2.2.3 Disseminated intravascular coagulation (DIC) 
ISTH has defined DIC as ‘an acquired syndrome characterized by the intravascular 
activation of coagulation with loss of localization arising from different causes. It can 
originate from and cause damage to the microvasculature, which if sufficiently 
severe, can produce organ dysfunction’.7 The term ‘overt DIC’ refers to 
uncompensated coagulation, i.e. a severe form of the coagulation disorder. ‘Non-
overt DIC’ is a milder coagulation disturbance with sufficient compensatory 
mechanisms.   
DIC is a syndrome triggered by a variety of conditions: infectious and inflammatory 
diseases, malignancies, severe organ destruction, vascular anomalies, obstetric 
emergencies and immunological and toxicological emergencies.56 Exaggerated 
global activation of coagulation occurs as a response to a systemic inflammatory 
reaction and/or a release of procoagulant material into the bloodstream. Briefly, in 
DIC, activation of microvascular endothelium and exposure of TF to circulating FVII 
leads rapidly to an overwhelming thrombin burst and formation of excessive 
amounts of fibrin, which malfunctioning natural anticoagulant and fibrinolytic systems 
cannot suppress.6,57  
The incidence of DIC depends on the underlying disease. In severe sepsis, DIC 
exists in about 30-40% of patients.58-60 In severe trauma, the incidence of overt DIC 
is somewhat lower, about 10% in the first 24 hours after trauma.61 The presence of 
DIC may roughly double the mortality in critically ill patients to approximately 
40%.59,62-64 Based on the pathophysiology of DIC, fibrin deposition and subsequent 
microthrombosis may obstruct microvasculature, thus contributing to the 
development of multiple organ dysfunction.65 Many studies show that the incidence 
and severity of DIC are directly correlated to the degree of organ dysfunction.62,64,66 
Major bleeding due to thrombocytopenia and low levels of coagulation factors is the 
most feared consequence. However, it seems to be rather infrequent. Subgroup 
analyses of DIC patients receiving placebo in large anticoagulant trials have 
revealed that incidence of any bleeding was approximately 11% and major bleeding 
occurred in only 3%.58,59 In an unselected cohort of critically ill patients, 
thrombocytopenia of any cause was associated with major bleeding in 20%.67 
2.3 DIAGNOSTICS OF COAGULOPATHY 
‘Traditional coagulation assays’ refer to easily accessible tests of blood coagulation 
capacity that measure the deficiency or consumption of the components. These 
tests include platelet count, prothrombin time (PT) with modifications, activated 
partial thromboplastin time (aPTT) and fibrinogen concentration. ‘Fibrin-related 
marker’ assays measure the extent of coagulation activation and fibrin formation. 
Measuring platelet count is the most performed test for primary evaluation of the 
haemostatic system. The blood sample is anticoagulated, and counting is performed 
by either impedance, optical or immunological methods. Low platelet count can be 
verified manually to exclude agglutination.68 
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PT assay is a coagulation screening test used for assessing liver function, 
recognizing deficiencies or consumption of certain coagulation factors and 
monitoring oral anticoagulant therapy. It was first described by Quick69 in 1935, and 
a later modification by Owren70 is widely used in Nordic countries. Both Quick- and 
Owren-type PT assays measure vitamin K-dependent coagulation factors (FVII, FX 
and prothrombin), but Quick-type PT is dependent on FV and fibrinogen as well. 
Owren-type PT is often reported as a percentage of activity of studied plasma 
relative to a commercial calibrator representing 100% activity. Often PT is reported 
as an international normalized ratio (INR).68 
APTT is a screening test for the deficiency of coagulation factors involved in 
‘intrinsic’ and common pathways (factors V, X, II, VIII, IX, XI and XII and fibrinogen). 
However, prolonged APTT does not necessarily indicate increased risk of 
bleeding.71  
D-dimer fragment is the terminal product of plasmin-induced degradation of cross-
linked fibrin, and it is derived from both intravascular and extravascular clots. In 
plasma, D-dimer forms a complex with other compounds. Different monoclonal D-
dimer assays recognize a mixture of D-dimer-containing complexes with variable 
sensitivity. Thus, numerical results from available commercial assays may vary 
widely.72 These fibrin degradation tests report on the active coagulation process and 
clot formation only indirectly. 
The main indication for fibrinogen assessment is active bleeding. In most cases, low 
levels indicate consumption of fibrinogen by blood loss or activated coagulation 
process. Fibrinogen concentration is measured in clinical settings by functional 
assays using, for example, the kinetic method of Clauss.73  
2.3.1 Different coagulation tests and their combinations in DIC 
Although pathophysiology of DIC has been extensively investigated, diagnosis of 
DIC on the basis of laboratory findings may be difficult. Combining and repeating the 
assays may increase specificity because none of the single routine assays alone is 
specific to DIC. A summary of the coagulation assays proposed in the diagnosis of 




Table 1. Laboratory tests in the diagnosis of DIC.  
Test Pathologic 
results in all ICU 
patients 
Pathologic 
results in DIC 
Specific comments 
Consumption of components   
Platelet count <150 x109 /l (LLN):  
35-44% of medical 
ICU patients3,32 
<150 x109/l (LLN):  
>95% 
<100 x109:  
50-60% 
<50 x109:  
10-15%74 
Hallmark of DIC diagnosis: low or 
declining platelet count.  
Thrombocytopenia strong 
independent predictor of ICU 
mortality regardless of origin.3 
Prothrombin time  INR >1.5:  
30% of ICU patients4 
 
PT>14.5 s (ULN):  
93% of patients with 
severe sepsis59,75 
 
>95%74,76 Not very sensitive to early (milder) 
consumption (pathologic result 
occurs when concentration of any 
coagulation factor concerned is 
below 50%).74 
 
PT is prolonged (Owren-type PT 





>39 s (ULN):  
63% of patients with 
severe sepsis75 
>95%59 Because of elevated FVIII and 
fibrinogen due to acute phase 
reaction, aPTT may be even 
shortened in the early phase of 
DIC.77 
Fibrin-related markers   
Fibrinogen  <1 g/l: 24% 
>2 g/l: 69% 78 
Acute phase protein.  
May be normal or elevated in early 
DIC.77 Elevated levels correlate 
with mortality and organ failure. 
D-dimer >0.4 (ULN):  
100% of patients 
with severe sepsis75 
100%59 High D-Dimer: low specificity. 
Normal D-dimer effectively rules 
out DIC. 
Problematic standardization due to 
several different assays.74,77 
Coagulation inhibition   
Antithrombin <80% (LLN):  
82% of patients with 
severe sepsis75 
>95%59 Potentially useful, but low 
specificity. Shown to be 
associated with mortality.23  
Not globally available.74,77 
Protein C <81% (LLN):  
87% of patients with 
severe sepsis75 
>95%59 Not globally available.77 
Soluble 
thrombomodulin 
>53 ng/ml (ULN): 
72% of patients with 
severe sepsis75 
>95%59 Available only in specific 
coagulation laboratories. 
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Table 1 (continued). Laboratory tests in the diagnosis of DIC. 
DIC, disseminated intravascular coagulation; ICU, intensive care unit; LLN, lower limit of 
normal; ULN, upper limit of normal; PT, prothrombin time; aPTT, activated partial 
thromboplastin time; AU, absorbance unit. 
2.3.2 DIC score and its evolution 
Previously, the diagnosis of DIC was based mainly on “expert opinion”, local 
guidelines and pathological changes in coagulation tests because a universal 
definition was lacking.79-84 In 2001, ISTH presented diagnostic criteria based on 
easily achievable ‘global’ coagulation assays.7 A prerequisite for the use of the score 
is an appropriate underlying diagnosis that may cause DIC. A combination of 
parameters (platelet count, PT in seconds, fibrin-related marker and fibrinogen) 
gives points according to their level. Diagnosis of overt DIC is justified if the total 
score is at least 5. Since 2001, many study groups have modified the ISTH score by 
varying laboratory tests or their cut-off values. The role of fibrinogen in the score has 
been debated because of its dual behaviour in critical illness.59,78,85 
In order to facilitate diagnosis of DIC, ISTH also suggested a template for a scoring 
system for stressed, but still compensated coagulation, non-overt DIC.7 The 
template takes into account both absolute values of coagulation tests and their 
changes. Unlike the score for overt DIC, the score for non-overt DIC includes 
specific markers like AT and PC.8,9,86  
As compared with an ‘expert opinion’, ISTH score recognizes overt DIC patients 
excellently and correlates well with degree of organ dysfunction and 28-day 
Test Pathologic 
results in other 
conditions 
Pathologic 
results in DIC 
Specific comments 




>37.8 AU/ml (ULN): 
44% of patients with 
severe sepsis75 
>95%59 Potentially useful, but available 
only in specific coagulation 
laboratories.74,77 
Other   
Fragment 1+2 >1.1 nmol/l (ULN): 
78% of patients with 
severe sepsis75 
>95%59 Not specific to DIC.  
Pre-analytic factors may strongly 
affect the results.  





>4.1 µg/l (ULN): 
96% of patients with 
severe sepsis75 
>95%59 Not specific to DIC.  
Pre-analytic factors may strongly 
affect the results.  
Available only in specific 
coagulation laboratories.74 
 25 
mortality.64 Several studies have assessed ISTH score against two other scoring 
systems: the Japanese Ministry of Health and Welfare (JMHW)87 and the Japanese 
Association for Acute Medicine (JAAM)88 scores. JAAM criteria seem to be most 
sensitive in the early diagnosis of DIC.60 JMHW and JAAM scores have high 
sensitivity for DIC of any aetiology, whereas ISTH score is the most specific, but 
may miss milder cases of DIC and even non-survivors.62 Table 2 summarizes 
different scores for DIC. 
No gold standard for the diagnosis of DIC exists. Recently, ISTH Scientific and 
Standardization Committee on DIC published a communication as an attempt to 
harmonize the different guidelines for DIC.89-92 The committee suggested the use of 
any score without setting any preferences. 
Table 2. Scoring systems for overt DIC.  
 
ISTH, International Society on Thrombosis and Haemostasis; JMHW, Japanese Ministry of Health and 
Welfare; JAAM, Japanese Association of Acute Medicine; HPT, haematopoietic malignancy; PT, 
prothrombin time; FDP, fibrin degradation products; ULN, upper limit of normal; LLN, lower limit of normal; 
SIRS, systemic inflammatory response syndrome.  
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<1.25 
<1.2 
ULN + 3-6s  
≥1.25 
≥1.2 










































Underlying disease, organ 
failure due to thrombosis:  +1 
point, bleeding symptoms in 
non-HPT patients: +1 point, 








2.4 POINT-OF-CARE HAEMOSTASIS TESTS 
Point-of-care test (POCT) refers to a diagnostic test that can be performed near the 
patient, and the results are readily available, improving patient care in rapidly 
changing situations.93 As POCTs are frequently performed by personnel without 
training for laboratory analytics, the procedure must be well controlled. The British 
Committee for Standards in Haematology has published guidelines to standardize 
conditions for POCT testing.94  
Although severe sepsis-related coagulopathy may not demand immediate actions 
unlike acute haemorrhage, POCT analyses, including thromboelastometry/ -graphy 
(TEM/TEG) may provide additional information on coagulation by visualizing clot 
formation as a continuous process.95 The ISTH Scientific and Standardization 
Committee on DIC has encouraged the study of applicability of POCTs in DIC. 
2.4.1 Methodology of rotational thromboelastometry   
Hartert96 introduced a classical TEG for research purposes in 1948. It took, however, 
several decades until TEG gained a foothold in clinical practice, first as a method to 
assess coagulation and decrease blood loss in liver transplantations and cardiac 
surgery.97,98 Development of the method over the years has led to different technical 
solutions. The main principle of different commercial devices is the same; the 
methodology produces bed-side a real-time graphical trace of visco-elastic forces 
during clot formation, giving information on initiation of coagulation, fibrin 
polymerization, clot strengthening and fibrinolysis. TEG summarizes the effect of 
coagulation factors, platelets, anticoagulants and fibrinolytic factors. 
Rotational TEM, ROTEM® (Tem International GmbH, Munich, Germany), is an 
application developed on the basis of the original TEG. Citrated blood sample is first 
pipetted into a plastic cuvette located in a prewarmed (37°C) cup holder. After 
adding necessary reagents to blood, an oscillating pin starts to rotate and form a clot 
between the cup and the pin (Figure 2). A graphical curve presents an optically 
detected change in viscosity of the sample (Figure 3). 
TEM tests assess different aspects of coagulation. The most common tests are: 
1. EXTEM: assesses the combined effect of extrinsic pathway coagulation 
factors and platelets. Citrated blood is recalcified after which TF-
containing reagent activates coagulation. EXTEM is not affected by 
heparin. 
2. FIBTEM: In recalcified blood, addition of TF triggers coagulation and 
cytochalasin D eliminates the effect of platelets. FIBTEM assesses 
firmness of a fibrin clot, and trace is mainly influenced by fibrinogen and 
factor XIII levels.  
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3. HEPTEM: Activation of coagulation occurs similarly to INTEM assay, 
but heparinase-containing reagent eliminates the effect of heparin. 
Comparison with INTEM reveals the effect of heparin.  
4. APTEM: In APTEM, addition of aprotinin inactivates plasmin 
immediately and prevents fibrinolysis. In the case of suspected 
hyperfibrinolysis, APTEM and EXTEM are compared.  
5. NATEM: Recalcified sample is allowed to coagulate without any 
activators in this original, non-activated TEM test. Not in clinical use. 
 
Figure 2. Detection method of TEM. 
Figure published with the permission of Tem International GmbH. 
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The following parameters can be derived from the graphic curve: 
1. Clotting time (CT): A period from the addition of the activating reagents 
until the recognizable trace of fibrin formation (amplitude of 2 mm) 
reflects initial fibrin formation.  
2. Clot formation time (CFT): A period from the first signs of clot 
formation until the clot formation trace reaches an amplitude of 20 mm. 
CFT reflects fibrin build-up and clot formation kinetics. 
3. Alpha angle (α): An angle between the baseline and the tangent of the 
trace at the point where the amplitude reaches 2 mm. α reflects the 
speed of clot formation. 
4. Maximal clot firmness (MCF): The maximal amplitude of thrombo-
elastometry trace reflects the strength of a clot and the combined effect 
of coagulation factors and platelets.  
5. Lysis index (LI): Percentage of amplitude at given time point relative to 
MCF reflects the speed of fibrinolysis.  
 
 
Figure 3. TEM curve with parameters. 
Figure published with the permission of Tem International GmbH.  
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2.4.2 Thromboelastometry/ -graphy in septic coagulopathy 
TEM/TEG has slowly gained popularity in acute and intensive care settings. The 
interest has been greatest among professionals who take care of trauma patients 
with rapid and marked changes in coagulation capacity.99-101 In unselected cohort of 
critically ill patients, hypocoagulation diagnosed by TEG predicted independently 30-
day mortality.102 
The few endotoxemia model studies have demonstrated quite consistently that 
activation of coagulation occurs more rapidly, but clot formation and clot strength are 
either reduced or not affected depending on the dose of lipopolysaccharide.103-105 In 
studies on septic patients TEM/TEG findings vary widely depending on the 
population, time course of the disease, chosen technology and the tests applied. 
Although at least minor coagulation activation occurs in virtually every patient with 
severe sepsis, only more marked disturbance is detectable with TEM/TEG. Thus, 
most studies examining severe sepsis patients as a homogeneous group have 
shown that TEM/TEG parameters either remain within reference ranges or 
demonstrate mild hypercoagulability.106-113 However, patients with more severe 
condition (SOFA score >10 or overt DIC) are hypocoagulable according to TEM, 
which is associated with a higher mortality.114,115 Some studies have reported 
inhibition of fibrinolysis in otherwise normocoagulable patients.109-112,116 Tables 3 
and 4 summarize the greatly varying study designs and the main results of 
experimental and clinical TEM/TEG studies. 
A recent systematic review assessed applicability of TEM/TEG in detecting sepsis-
related coagulation disorders and in predicting outcome.117 The authors conclude 
that hypocoagulability as detected by TEM/TEG may aid in diagnosing DIC and 
predicting mortality, but diagnostic accuracy of TEM/TEG in general sepsis-related 




Table 3. Endotoxemia studies on rotational TEM. 
 
TEM, thromboelastometry; LPS, lipopolysaccharide; CT, clotting time; CFT, clot formation 
time; MCF, maximal clot firmness; ML, maximal lysis; PT, prothrombin time, aPTT, activated 






Study Objects TEM tests Design Results 






induced by bolus 
of LPS (2 ng/kg) 
 
Blood samples at 
0, 1, 2, 3, 4, 6, 8 
and 24 hours 
CT: ↓ until 6 hours, 
after which changes 
diminished. 
CFT: no change 
MCF: no change 
ML: 3.9-fold ↑ at 2 
hours 
Traditional tests: 









induced by a 
bolus and infusion 
of LPS (>200 
µg/kg). 
 
Blood samples at 
0 and 60 minutes. 
 
CT: ↓ in INTEM, but 
was unchanged in 
EXTEM 
CFT: ↑ both in EXTEM 
and in INTEM 
MCF: ↓ in all tests 
Traditional tests:  










induced by LPS 
infusion (ad 10 
µg/kg). 
 
Blood samples at 
0, 1, 2, 3, 4 and 5 
hours 
CT: ↓ until 3 hours, 
after which changes 
diminished. 
CFT: ↑ until 5hours 
MCF: ↓until 5 hours 
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Table 4. Clinical studies on TEM/TEG in human sepsis. 
  




n= 38  
severe sepsis 









• CT ↑, MCF and α ↑: 
activation of clot 
formation delayed, 
but once initiated, 

















prior AT and 
then daily  
• Reaction time: ↓ 
Coagulation time: ↓, 
Maximal amplitude: ↑ 
• Hypercoagulation 

















at 0, 12, 24 
and 48 hours 
• Results within 
reference values 
• SOFA>10 vs. <10:  
MCF ↓, CFT ↑, α: ↓, 




n=21 overt DIC 











• TEM score for DIC: 1 
point for each 
hypocoagulable TEM 
parameter. 
• TEM score ≥2: ROC 
AUC 0.957 (0.902-





















• Sepsis vs. controls: 
CT ↓, CFT↓, α ↑; 
MCF no change 
• Postoperative: 
hypercoagulability 
• LI: ↑ sepsis vs. 
postoperative and 
controls → inhibition 
of fibrinolysis. 
• LI ROC AUC 0.901, 
OR 85.3 for severe 
sepsis 
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Table 4 (continued). Clinical studies on TEM/TEG in human sepsis. 
 
  













• In non-survivors: 
CT unchanged; 
CFT↑; α↓; MCF↓ 
• Changes in CFT, α, 
MCF predict 30-day 
mortality better than 















on days 1,2, 
4,7,14 and 28 




• MCF ↑ (FIBTEM), 
CT ↑ (INTEM) and 
LIs ↑ (EXTEM) 
• Non-DIC sepsis 
patients 
hypercoagulable 











prior to the 
operation and 
once daily until 
day 6 











at 0 and 6 
hours, and on 










• Prediction of hospital 
mortality: aPTT, TG 
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Table 4 (continued). Clinical studies on TEM/TEG in human sepsis. 
 
 
aPTT, activated partial thromboplastin time; AT, antithrombin; AUC, area under curve; CT, 
clotting time; CFT, clot formation time; DIC, disseminated intravascular coagulation; LI, lysis 
index; MA, maximal amplitude; MCF, maximal clot firmness; ML, maximal lysis; OR, odds 
ratio, PT, prothrombin time, ROC, receiver operating characteristics; SAPS, Simplified Acute 
Physiology Score; SOFA, Sequential Organ Failure Assessment; TG, thrombin generation; 
TEG, thromboelastography; TEM, thromboelastometry; ULN, upper limit of normal.  









on days 1,2,3 
and 4 
• 22%/ 48% / 30% 
hypo- /normo- 
/hypercoagulable 
• TEG constant until 
Day 4 
• Hypocoagulable MA 
predicted 28-day 
mortality 
• Reduced platelet 
contribution to MA in 














on days 1,2,3 
and 7 
• Normocoagulability 
in ROTEM, mild 
hypocoagulation in 
PT, aPTT and 
platelet count. 














and daily until 
day 5 
• TEG stable for 5 
days 
• Fibrinogen MA ↑ 
• Most patients: 
















and daily until 
day 3 
• Inhibition of 
fibrinolysis correlated 




2.5 ORGAN DYSFUNCTION 
2.5.1 Sepsis and multiple organ dysfunction  
‘Sepsis’ refers to a host response to a suspected or confirmed infection, manifested 
by at least two of the four criteria of systemic inflammatory response syndrome 
(SIRS). Sepsis is graded as ‘severe’ when hypoperfusion, hypotension or any organ 
dysfunction coexists. In ‘septic shock’, sepsis-induced hypotension despite adequate 
fluid resuscitation occurs, and signs of hypoperfusion exist. Severe sepsis may lead 
to multiple organ dysfunction syndrome (MODS) in which function of more than one 
organ is defective and the organs are unable to maintain homeostasis.40,41 MODS 
accounts for the high mortality seen in the critically ill.120  
According to a recent review, the hallmark of MODS is a hyperinflammatory 
response to a triggering incident. First, exaggerated production of proinflammatory 
mediators results in universal dysfunction of endothelial cells and adhesion of 
leukocytes to the activated endothelium. Secondary mediators and reactive oxygen 
species amplify this reaction. Later, intrinsic inflammatory cells in the organs sustain 
the inflammation.121 Different organs respond to inflammatory mediators in typical 
ways, others being more vulnerable to the development of dysfunction.122-124 
2.5.2 Acute kidney injury 
Acute kidney injury (AKI) is defined as a ‘common syndrome with an abrupt 
decrease in kidney function, which includes, but is not limited to, acute renal failure. 
AKI may arise from various aetiologies, including pre-renal causes, acute specific 
kidney processes and post-renal obstructive nephropathy’.125 Manifestation of AKI 
forms a continuum from minor biomarker changes to full-blown acute failure of 
kidney function requiring RRT.  
To rein in multiple and conflicting definitions for AKI, three subsequent, widely 
acknowledged criteria for AKI have been published since 2004: the Risk, Injury, 
Failure, Loss and End-stage renal disease (RIFLE) classification,126 the AKI Network 
criteria (AKIN)127 and, last, the Kidney Disease: Improving Global Outcomes 
(KDIGO) criteria.125,128 
Even small rises in blood creatinine level are associated with an increase in 
mortality,129-131 and severity of AKI is correlated with increasing mortality.132,133 In a 
mixed population of 2901 critically ill patients in the FINNAKI study, 90-day mortality 
ranged from 29% to 39% with advancing AKI stages.133 Poukkanen et al.43 showed 
that in severe sepsis AKI developed in 53%, and the 90-day mortality of the patients 
with AKI was 38% compared with 25% in those without.  
 
Development of AKI is often multifactorial. Several large studies have revealed that 
age, hypotension for any reason, sepsis or septic shock, cardiogenic shock, 
mechanical ventilation, coagulation disorders, need for and use of vasoactive drugs, 
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certain nephrotoxic agents and coexistence of other organ failures predispose to 
AKI.133-135 
2.5.3 Microvascular thrombosis versus local cell dysfunction 
Historically, sepsis-associated DIC and microvascular thrombosis were claimed to 
result in, rather straightforwardly, obliteration of blood circulation of different organs, 
and thus, multiple organ dysfunction.56,65 Several studies on autopsy cases of DIC 
have revealed widespread microthrombosis in multiple organs.136-139 However, in the 
studies of Watanabe et al.138 and Tanaka et al.,139 DIC was defined on a 
pathological basis. In addition, the studies revealed numerous patients with clinically 
suspected DIC and no thrombosis (67/109 cases),139 as well as those with 
microthrombosis without clinical suspicion of DIC (38/51 cases).138  
Recent reviews assemble data on experimental and human studies, which 
demonstrate the connection between altered coagulation and development of organ 
dysfunction.140,141 In baboon and rabbit models of lipopolysaccharide (LPS)-induced 
DIC, administration of TF-inhibitor and inhibition of PAI-1 could prevent acute lung 
injury and renal fibrin deposition.142-145 In a murine model, inactivation of t-PA and u-
PA genes led to an increased risk of fibrin deposition in many organs and higher 
incidence of venous thrombi.146 In a rodent model of AKI, blocking of PAR-2, a 
molecule with well-known interactions between inflammation and coagulation, 
inhibited formation of renal fibrin deposits, but no attenuation occurred in renal 
dysfunction.147 Also, complete blocking of factor Xa failed to prevent baboons from 
developing organ damage and dying from experimental Escherichia coli sepsis, 
suggesting that other inflammatory aspects may be responsible for negative 
outcome.148 In humans, evidence originates from studies on patients with severe 
sepsis; DIC contributes to the development of organ dysfunction and is associated 
with increased mortality.81,149,150   
Despite widespread activation of coagulation, microthrombosis is likely not a 
predominant factor in the alterations of microcirculation in sepsis.151 Recently, 
Gomez et al.152 presented their unified theory of sepsis-induced AKI. In brief, 
inflammatory danger signals launch the adaption of tubular cells; microvascular 
dysfunction and inflammation amplify this process, and mitochondria initiate cell 
survival process at the expense of renal function. 
Pathophysiology of AKI is still not fully understood, and even histological findings 
remain controversial. Although many conditions associated with AKI may manifest 
as global or local ischaemia, hypotension or hypoperfusion, septic AKI more 
probably arises from cell-based factors. Mariano et al.153 have shown that plasma, 
derived from septic patients with AKI, induced apoptosis, reorganized the 
cytoskeleton and altered the cell polarity in tubular cell culture.  
A recent systematic review evaluated both human and experimental data and found 
that acute tubular necrosis was rather uncommon.154 Septic AKI, induced by 
intravenous infusion of Escherichia coli, did not present any macroscopic 
histopathological findings in sheep as compared with controls.155 In mice, caecal 
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ligation and puncture induced only minimal acute tubular necrosis, but tubular cell 
apoptosis was very common and correlated with renal dysfunction.156  
Lerolle et al.157 studied post-mortem kidney biopsies of 19 consecutive patients who 
died of septic shock and AKI. Fibrin depositions were present in the renal capillaries 
in 42%, complete or partial thrombi in the afferent artery in 21% and glomerular 
capillary thrombi in only one patient.  Other findings were signs of tubular cell 
apoptosis in all patients, tubular lesions and only minimal inflammation in the 
interstitium. Remarkably, patients with and without overt DIC had fibrin depositions 
equally.157 By contrast, Takasu et al.158 have questioned a predominant role of 
apoptosis in the formation of tubular injury. Instead, they revealed transient injury 
and focal necrosis of tubular cells, mitochondrial injury and signs of tubular 
regeneration.   
2.5.4 Natural anticoagulants in preventing organ dysfunction 
The idea of preventing organ dysfunction and thereby improving outcome by 
restoration of disturbed coagulation by limiting thrombin generation with natural 
anticoagulants has unfortunately led to disappointments in numerous clinical trials. 
Supplementation of recombinant TFPI (OPTIMIST study), AT (Kybersept study) and 
aPC (PROWESS and PROWESS SHOCK studies) in severe sepsis could not 
reduce 28-day mortality in large, clinical, multi-centre studies.159-162 These trials have 
been criticized for overly heterogeneous patient populations, rigid dosing, 
suboptimal time frames and coincidental administration of other anticoagulants.163,164 
However, quite recently, phase IIb trial on soluble thrombomodulin (s-TM) in severe 
sepsis patients with concomitant DIC provided promising results, and a phase III trial 
is ongoing.165 Other studies on s-TM in haematologic patients with DIC and patients 
with severe sepsis have revealed that s-TM may decrease mortality and organ 
dysfunction by resolving DIC.166-168 TM has both anticoagulant and cytoprotective 
function. In addition to activation of PC, which possesses well-known anti-
inflammatory and anti-apoptotic functions, TM binds harmful HMGB1 and histones 
and contributes to the inactivation of complement.24,169-172 
2.5.5 Histones  
Histones are proteins normally located in the cell nucleus. Two histone H2A-H2B 
dimers and one histone H3-H4 tetramer form a condensed, disc-shape structure, a 
nucleosome, which folds nuclear DNA around this complex by a linker histone H1. 
The main functions of nucleosomes are to organize and stabilize DNA strands, to 
regulate transcription and replication and to participate in the DNA repair 
process.173,174 
Histones may access extracellular space and circulation by rupture of cell and 
nuclear membranes in cell death or by active secretion. In the healthy body, a small 
amount of apoptosis, an organized cell death, occurs continually throughout life.175 
Apoptosis is responsible for cell renewal and tissue homeostasis. In apoptosis, the 
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cell membrane retains its integration, and apoptotic cells package cell-derived 
constituents and release them to the extracellular space. In necrosis (also known as 
oncosis), cell death is unorganized; the cell membrane disrupts and the cell releases 
intracellular contents into extracellular space, and various enzymatic reactions begin 
to digest the compounds. Nowadays, also mixed forms of cell deaths are 
recognized.173  
In inflammation, proinflammatory cytokines may promote necrosis of activated 
neutrophils (NETosis) and other leukocytes (ETosis).176,177 This process spreads 
intranuclear compounds, including nucleosomes and histones, to the extracellular 
space, where they form neutrophil extracellular traps (NETs). These components of 
innate immunity are responsible for killing micro-organisms.178 
Extracellular histones may appear as small complexes with DNA, mono- and 
oligonucleosomal fragments, larger DNA-bound fragments, complexes with NETs 
and free.173,179 Histones are positively charged ions and bind easily to negatively 
charged ions, also others than DNA: C-reactive protein (CRP),180 lipopolysaccharide 
(LPS),181 high-mobility group box 1 (HMGB1)182 and heparin sulphate 
proteoglycans.183,184 
Extracellular histones have several deleterious effects. Most importantly, 
extracellular histones damage host cells, and thus, may cause organ dysfunction in 
inflammatory diseases. Mice challenged with histones developed fatal changes in 
their lung tissue.185 Recently, Allam et al.186 showed that injection of histones into the 
renal artery resulted in widespread necrosis of the renal cortex and medulla, 
whereas inhibition of histones with neutralizing antibody decreased AKI in LPS-
induced endotoxemia in mice. At the moment, it is widely accepted that histones 
may play a major role in development of septic AKI.187  
Several studies have linked extracellular histones to disturbed coagulation. Histone 
H4 is a potent promoter of platelet aggregation, and it has caused thrombocytopenia 
in murine sepsis models.170,188,189 Studies in the critically ill have presented more 
conflicting results.  Nucleosomal histone-complexed DNA (hcDNA) levels have been 
associated with a degree of coagulopathy in patients with severe trauma.190,191 In 
severe sepsis, one study has reported an association between hcDNA and markers 
of coagulopathy,192 and another between extracellular histones H4 and decline in 
platelet count.193 Quite recently, a mixed population with overt DIC (the majority of 
whom were not critically ill patients) was shown to have higher levels of circulating 
hcDNA and double-stranded DNA than patients without DIC. HcDNA also correlated 
with D-dimer and predicted 28-day mortality with an area under curve (AUC) of 
0.700. 194 Table 5 summarizes experimental sepsis studies with special reference to 
coagulation. Table 6 presents studies on histones in the critically ill.   
2.5.6 High-mobility group box 1 
A non-histone chromatin-associated protein, HMGB1, acts as a strong 
proinflammatory cytokine and a late mediator of lethal consequences in severe 
sepsis when released into the intravascular space.195,196 In inflammation, several 
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immune cell types actively secrete HMGB1.197 However, a controversy long existed 
about whether necrotic cells only passively release HMGB1 or whether HMGB1 
release also occurs in apoptotic cell death.198,199 Extracellular HMGB1 binds to four 
receptors: receptor for advanced glycation end-products (RAGE), toll-like receptors 
2 and 4 (TLR2 and TLR4) and syndecan-1.197 Of these, TLR4 is a primary receptor 
that mediates proinflammatory functions.200 Once released, HMGB1 concentration 
stays elevated for days, which makes it an intriguing target for inhibitor trials.196,201 
HMGB1 enhances inflammatory reaction by activating nuclear factor-ΚB and up-
regulating TNF-α.202 It also interacts with coagulation and may contribute to organ 
failure. Ito et al. 203 showed that in a murine DIC model, mice developed more 
excessive glomerular fibrin deposition if thrombin was administered with HMGB1. In 
critically ill patients suspected of having DIC, HMGB1 levels correlated with DIC and 




Table 5. Experimental studies on nucleosomes and histones in severe inflammation 
models. 
  
LPS, lipopolysaccharide; aPC, activated protein C; AKI, acute kidney injury; CRP, C-reactive 
protein; AT, antithrombin; rTM, recombinant thrombomodulin. 
Study Design Results 
Xu 2009 185 Murine and baboon 
sepsis models with 
histones, LPS, histone 
antibodies, aPC 
 
• Extracellular histones cytotoxic to endothelium 
• aPC degrades histones 
• aPC may degrade also DNA-bound histones 
• Toxicity mainly due to H3 and H4 
• In a baboon model, H3 was associated with 
onset of AKI 
• aPC injection of recombinant aPC rescued all 
histone-challenged mice 
• Histology: microvascular thrombosis, fibrin 
deposition, collagen accumulation 
Fuchs 2011 188 Murine model of sepsis; 
murine and human 
blood, platelets and 
plasma; histological 
analysis 
• Histones induced platelet aggregation in the 
presence of fibrinogen (more) or plasma (less) 
• H4 more potent than H1, H2A, H2B and H3 
• Histones induced thrombocytopenia 
• Histones were lethal also in platelet-depleted 
mice 
• Heparin inhibited histone-platelet interaction 
Lam 2013 189 Blood from healthy 
volunteers 
Platelet aggregometry 
Challenge to H4 and 
albumin 
• Histone H4 induced aggregation of washed 
platelets 
• Plasma inhibited aggregation 
• Albumin-depleted plasma inhibited aggregation 
less than normal plasma 
Nakahara 2013 170 Murine model with 
histone challenge 
• Histones caused thrombocytopenia 
• Citrate inhibited platelet aggregation 
• Platelet depletion protected from death, but the 
effect diminished over time, suggesting other 
mechanisms instead of mere thrombosis 
• Recombinant thrombomodulin (rTM) protected 
mice against fatal pulmonary embolism 
Abrams 2013 205 Murine model with 
histone and CRP 
challenge 
Sera from patients with 
trauma, pancreatitis and 
severe sepsis 
• CRP inhibited histone-induced endothelial 
damage and platelet aggregation 
• Patient sera with either endogenous or 
exogenous CRP elevation inhibited histone-
induced endothelial toxicity 
Kowalska 2014 206 Murines challenged with 
histones, platelet factor 
4 (PF4) and heparinoids 
• Histone challenge increased aPC formation 
• In sepsis and severe sepsis added heparinoids 
behave differently depending on histone and 
PF4 levels: in severe sepsis, non-anticoagulant 
heparinoid increases endogenic aPC 
production 
Iba 2014 207 Rodent LPS-model with 
antithrombin (AT) and/or 
rTM substitution 
• Combination therapy (AT+rTM) reduced histone 
H3 and cell-free DNA levels; less organ 
damage 
• Fewer dead cells in combination therapy group 
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Study Patients Design Results 
Zeerleder  
2003 208 
n=15 with fever 
n=15 with SIRS 
n=32 with severe sepsis 






Nucleosome levels ↑ in 81%, 
correlated with 
severity of inflammation. 
No correlation with cytokines 
and coagulation tests 
Chen 2012 209 Surgical ICU 
Cohort 1:  






within 24 hours of 
admission 
Sepsis vs. severe sepsis vs. 
septic shock; 35% with sepsis 
Nucleosomes predicting sepsis: 
ROC AUC 0.67 (0.55-0.79), 
independent predictor of sepsis 
No correlation with sepsis 
severity or interleukins 
Correlation with APACHE II 
Kutcher 2012 190 n=132 critically injured 
trauma patients 
Plasma samples at 
admission and at 6 
hours 




Patients with higher histone 
level has higher trauma score, 
lower GCS, more MOF, and 
acute lung injury, longer need 
for ventilator support, higher 




n=38 children with 
meningococcal sepsis 




Nucleosomes elevated in non-
survivors 
PC treatment had no effect 
Johansson 2013 
191 
n=80 trauma patients hcDNA, biomarkers 
of coagulation, 
endothelial injury at 
admission 
Higher hcDNA associated with  
higher trauma score, D-dimer, 
tPA. 
APTT ↑,PAI-1 ↓, F 1+2 ↓ 












sTM, PC, PAI-1 and hcDNA 
strongest correlation with 
disease severity, coagulopathy 
and shock 
hcDNA correlated with lactate  
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Table 6 (continued). Human studies on nucleosomes and histones in the critically 
ill. 
 
APACHE, Acute Physiology and Chronic Health Evaluation; aPTT, activated partial 
thromboplastin time; AUC, area under curve; F1+2, factor 1+2; GCS, Glasgow Coma Scale; 
hcDNA, histone-complexed DNA; ICU, intensive care unit; MOF, multiple organ failure; PAI-1, 
plasminogen activator inhibitor-1; PC, protein C; ROC, receiver operating characteristic; 
SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure 














Study Patients Design Results 
Ekaney 2014 193 Cohort 1:  
n=15 severe sepsis 
Cohort 2: 
n=19 abdominal sepsis 
Controls: 
n=48 wo sepsis, with 
MOF, small trauma, 
multiple trauma, healthy 
Samples:  
On day 1, 3 and 5 
(cohort 2) 
Tests:  





H4 elevated in sepsis vs. ICU 
controls (also MOF) 
Multiple trauma 3-fold level  
Platelets ↓ <-> H4 ↑ 
Non-survivors had higher H4. 
SOFA and white blood cells 
predicted H4 level 
aPC: inverse correlation with H4 
Half-life of histones 4.6 minutes 
Kim 2015 194 n= 121 malignancies 
n= 31 sepsis 







53/199 overt DIC 
hcDNA and double-stranded 
DNA elevated in overt DIC 
HcDNA correlated with DIC 
score and predicted poor 
prognosis 
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2.6 MATRIX METALLOPROTEINASES (MMPs) 
2.6.1 MMP family 
MMPs form a growing family of zinc-dependent endopeptidases with structurally 
uniform features and a capability of degrading extracellular matrix (ECM). Both 
transcription and secretion of most MMPs are tightly regulated by several intra- and 
extracellular factors. Cells secrete most MMPs as inactive zymogens, which are 
activated by many different serine-proteases or other activated MMPs in 
extracellular space.211  
Traditionally, MMPs were classified according to their localization or substrates into 
subgroups: collagenases (MMP-1, -8, -13 and -18), gelatinases (MMP-2 and -9), 
stromelysins (MMP-3, -10 and -11), matrilysins (MMP-7 and -26), membrane-type 
MMPs (MMP-14, -15, -16, -17, -24 and -25) and others.212 MMPs may degrade 
many substrates not only in ECM but also in other locations, thus having much more 
complicated functions than originally expected.213 MMPs play a role in several 
inflammatory conditions,214,215 chronic kidney fibrosis,216 wound healing,217 
pulmonary diseases,218,219 arthritis,220 dental diseases,221 tumour formation and 
progression,222 atherosclerosis,223 cardiovascular diseases,224 and vascular225 and 
bone remodelling.226 
2.6.2 MMP-8 
In 1968, Lazarus et al.227 first discovered MMP-8, a granulocyte-derived enzyme that 
cleaved collagen. MMP-8 is known as ‘neutrophil collagenase’ as it is released by 
activated neutrophils, and for a long time, the only known substrates were collagens 
(types I, II and III). Activated MMP-8, however, degrades a great variety of 
molecules: α2-macroglobulin, substance P, fibrinogen, angiotensins I and II, plasmin 
C1-inhibitor and many others.212,228 Several cell types, including neutrophils, 
macrophages, plasma cells, several epithelial cells, endothelial cells, fibroblasts and 
myocytes, express MMP-8.228  
MMP-8 has a bidirectional function in many diseases. MMP-8 can have both pro- 
and anti-inflammatory functions.229,230 It can also either promote or inhibit tumour 
progression in different cancers.231,232 MMP-8 has been shown to over-express in 
rupture-prone atherosclerotic lesions, and contribute to the development of lung 
fibrosis and wound healing.233-235  
2.6.3 MMPs in sepsis 
Several MMPs have been shown to interact with complex inflammatory reactions on 
many levels.236 Experimental studies demonstrate that several MMPs are up-
regulated in severe infection models, and the presence of MMP inhibitors or 
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depletion of MMP-coding genes almost uniformly leads to better survival and less 
organ failure.230,237-239 Table 7 summarizes the most relevant studies on MMPs and 
tissue inhibitors of metalloproteinase (TIMPs) in patients with severe sepsis or in 
experimental models. 
2.6.4 Tissue inhibitor of metalloproteinase-1 (TIMP-1) as a biomarker 
Four TIMPs, logically numbered in order of their discovery, inhibit all MMPs by 1:1 
molar ratio. TIMP-2, TIMP-3 and TIMP-4 are unspecific inhibitors of all MMPs, 
whereas TIMP-1 has a lower affinity to membrane type MMP-1, -3 and -5 and MMP-
19.240 In addition to enzymatic MMP-regulating activity, TIMPs have been suggested 
to contribute to cell growth and differentiation and to also have anti-apoptotic 
functions.212 Furthermore, several proteins besides TIMPs inhibit MMPs.241  
A recent study on sepsis-induced DIC in murine caecal ligation and a puncture 
(CLP) sepsis model revealed that TIMP-1 increased early after CLP and onset of 
coagulopathy.242 Genetic polymorphism of the TIMP-1 gene resulted in a higher 
TIMP-1 level and increased mortality in patients with severe sepsis243 TIMP-1 has 





Table 7. Experimental and clinical studies on MMPs and TIMPs in sepsis models 
and in severe sepsis patients.    
Study Objects Design Results 
Vandenbroucke 
2012 230 








Unselective MMP inhibition 
protected mice from death 
MMP-8 -/- protected mice 
(LPS-model). 
MMP-8 not responsible for 
vascular disintegrity in organs 
despite CNS. 
MMP depletion reduces CNS 
inflammation. 
MMP-/- mice: less 
coagulopathy, kidney damage 
and MOF. 




MMP-8 AA genotype had a 
significantly stronger 
inflammatory reaction than 
AG and GG genotypes. 







1, -2 on day 1 
TIMP-1 discriminated non-
survivors with an AUC 0.78. 
MMP-2, -9 and TIMP-2 no 
association with APACHE II, 
no difference between 








within 2 hours of 
diagnosis 
TIMP-1 and MMP-10 higher in 
sepsis; TIMP-1 predicted 








MMP-2, -8, -9,  
TIMP-1 (serum) 
On days 1, 4, 6, 
8, 10 
MMP-2 and -8 higher and 
MMP-9 lower in severe 
sepsis. No correlations 
between APACHE, SOFA or 
mortality and MMP-8. 
Tressel 2011 239 Severe sepsis 
(n=50) 
 
Par1-/- and +/+ 
mice 
Murine model: 
LPS or CLP 
 
MMP-1 8.7-fold elevation, 
independent predictor of DIC 
and mortality. 
Mice: MMP-1 inhibition 
improved survival PAR-1-
dependently. MMP-1-
inhibition: less inflammation 
and DIC. 





1 (serum) at ICU 
admission 
MMP-8 and TIMP-1 higher  










TIMPs -1,-2,-4, on 
days 0-7 
All MMPs and TIMPs elevated 
in severe sepsis; MMP-9 had 
negative correlation with 
disease severity.  
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Table 7 (continued). Experimental and clinical studies on MMPs and TIMPs in 
sepsis models and in severe sepsis patients.   
 
APACHE, Acute Physiology and Chronic Health Evaluation; aPTT, activated partial thromboplastin time; 
AUC, area under curve; CLP, caecal ligation and puncture; CNS, central nervous system; DIC, 
disseminated intravascular coagulation; ICU, intensive care unit; INR, international normalized ratio; LPS, 
lipopolysaccharide; MMP, matrix metalloproteinase; MOF, multiple organ failure; NGAL, neutrophil 
gelatinase-associated lipocalin; PAI, plasminogen activator inhibitor; PAR, protease-activated receptor; 
SNP, single-nucleotide polymorphism; SOFA, Sequential Organ Failure Assessment; TIMP, tissue 
inhibitor of metalloproteinase.  
Study Objects Design Results 




1, -2 on days 1-5. 
MMP-2 no change, MMP-9 
and TIMP-1 higher. All 
markers decreased over time. 
Solan 2012 238 Children with 





2. cohort: septic 
shock (n=180) 
MMP-8 -/- mice 
Human samples 
at admission and 





Human: MMP-8 higher in 
more severe sepsis. 
Correlation with mortality and 
number of organ failures 
 
MMP-8 -/-(knock-out) and 











markers on day 1. 
TIMP-1 higher in non-
survivors and independent 
predictor of 30-day mortality.  
Patients with TIMP-1 T-allele 
had higher TIMP-1 levels and 
higher mortality. 




All: plasma within 
24 hours 
Subgroup:  
days 1,3 and 7. 
MMP-1, -2, -3, -8, 
-9, -10, -13, 
TIMPs 
MMP SNPs 
MMP-3, -8, -10 and TIMP-2 
higher in sepsis. MMP-9 
lower. 
TIMP-1 no change between 
patient groups.  
MMP-1 and  -13 SNPs 








Days 1, 4, 8. 
Non-survivors: TIMP-1 ↑, 
MMP-9 ↓,  
TIMP-1/MMP-9 ratio ↑. 
TIMP-1/MMP-9 ratio 
correlated with PAI-1, SOFA, 
platelets, INR, aPTT. 











TIMP-1 predicted 28-day 
mortality well (AUC 0.845), 
NGAL well (AUC 0.833), 
MMP-9 poorly (AUC 0.700). 
All those independent 
predictors of 28-day mortality. 
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2.6.5 MMPs in coagulation 
MMPs have many interactions with coagulation. Platelets express and store several 
MMPs (e.g. MMP-1, -2, -3 and possibly MMP-9) in cytoplasm, granules or on their 
surfaces.253-258 In platelets exposed to collagen, surface-bound collagenase, MMP-1, 
starts to activate PAR-1 and promote platelet aggregation.259 MMP-1-PAR-1 
interaction disrupts the endothelium, thereby increasing vascular permeability and 
exposure of tissue factor and collagen. In the study of Tressel et al.,239 MMP-1-
depleted mice had a suppressed cytokine storm and less DIC. MMP-2 has been 
suggested to enhance other pro-aggregatory mechanisms, and prime platelets for 
aggregation.260,261 MMP-9, by contrast, may inhibit platelet aggregation by opposing 
MMP-2 activity.262  
Although not involved in platelet aggregation, MMP-8 may contribute to the 
coagulation process at several other stages. Cunningham et al.263 showed in 
laboratory conditions that MMP-8 degraded TFPI by a proteolytic mechanism 
different from collagen cleavage. By degradation, TFPI fragments lost their ability to 
inhibit FXa, which may have significance also in vivo.264 Belaaouaj et al.265 
demonstrated similar TFPI degradation effect for MMP-7, -9 and -12 in addition to 
MMP-8. Hiller et al.266 showed in vitro that MMP-8, -12, -13 and -14 could 
proteolytically degrade fibrinogen, resulting in substantially impaired clot formation. 
All studied MMPs, except MMP-8, also cleaved and thereby inactivated FXII.266 In a 
murine model of endotoxemia, LPS-induced coagulation disturbance was more 
pronounced in mice with MMP+/+ genotype than in MMP-depleted mice.230 
The fibrinolytic system interacts with MMPs as well.267,268 MMP-9 may bind to fibrin 
and become activated by the plasminogen/plasmin system.267,269 MMP-3, MMP-7 






3. AIMS OF THE STUDY 
 
The main objectives of this study were as follows:  
 
1. To evaluate the incidence of DIC, the structure and validity of the ISTH 
score and simultaneous plasma antithrombin activity in a) diagnosis of overt 
DIC and b) prediction of 28-day mortality in a group of unselected critically ill 
patients (I). 
2. To investigate whole-blood coagulation profile with TEM (ROTEM ®) in 
patients with severe sepsis with or without overt DIC and to assess the 
applicability of TEM in the diagnosis of overt DIC (II). 
3. To investigate the levels of serum MMP-8 and its inhibitor, TIMP-1, and their 
associations with different coagulation assays in patients with severe 
sepsis-associated DIC (III). 
4. To evaluate whether systemic nucleus-derived histone-complexed DNA and 
HMGB1 can predict development of thrombocytopenia, development of AKI 










4. PATIENTS AND METHODS 
4.1 PATIENTS 
The Ethics Committee of the Department of Surgery in Helsinki University Hospital 
approved all study protocols. In Study I, the Ethics Committee waived the need for 
informed consent. In Studies II-IV, all patients or their next-of-kin gave informed 
consent. Table 8 summarizes the patients and the designs of Studies I-IV. 
Table 8. Designs of Studies I-IV. 
 
DIC, disseminated intravascular coagulation; ICU, intensive care unit; RRT, renal replacement 
therapy. 




























N = 494, of 
whom  
n = 306 with 
DIC associated 
diagnosis 
N = 28, of whom 
n = 16 no DIC  
n = 12 with DIC 
 
N = 22, of whom 
n = 13 no DIC  
n = 9 with DIC 
 
N = 225, of 
whom 
n = 75     
platelets <100 






admitted to the 
ICU  
Severe sepsis at 
admission 
Age 18-70 years 
Adult patients 
with severe 





























- n = 10 n = 10 - 
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4.2 STUDY DESIGNS AND MAIN OBJECTIVES 
Study I  
In this retrospective cohort study, data were collected from all patients admitted to 
the medical-surgical ICU of Helsinki University Hospital during the 22-month study 
period. Locally modified ISTH score for overt DIC was calculated daily in those 
patients who had a diagnosis known to be associated with DIC (sepsis, major 
trauma, organ destruction, haematological or solid malignancy, severe obstetrical 
complication, severe hepatic failure or severe toxic reaction). The main aim was to 
assess constitution and validity of the ISTH score and simultaneous plasma 
antithrombin activity in the diagnosis of overt DIC and in predicting 28-day mortality 
in a group of unselected critically ill patients.  
Study II  
In this prospective pilot study, we collected blood samples from patients with severe 
sepsis at admission. Thromboelastometric analyses and global coagulation assays 
were performed on admission to the ICU. We assessed the whole-blood coagulation 
profile of patients with or without DIC and healthy controls and compared the results 
of thromboelastometric analyses with global coagulation assays. We evaluated 
thromboelastometry parameters and their combinations with regard to diagnosis of 
overt DIC. 
Study III  
Study III was a prospective pilot study. We collected blood for MMP-8, TIMP-1 and 
routine coagulation assays from patients with severe sepsis on days 1 (day of 
admission), 2, 4 and 7. We compared serum MMP-8 and TIMP-1 concentrations in 
patients with or without overt DIC and healthy controls and assessed correlations 
with disease severity and traditional coagulation assays.  
Study IV 
Study IV was a sub-study of a large, multi-centre, prospective, observational cohort 
study, the FINNAKI Study, on the incidence, risk factors and outcome of AKI in 
Finnish ICU patients. We collected plasma from 225 consecutive patients who met 
the criteria for a diagnosis of severe sepsis within 24 hours of admission to the ICU 
and analysed systemic histone-complexed DNA and HMGB1 levels on admission 
(n=225) and at 24 and 48 hours (n=49). 
4.3 DEFINITIONS AND DISEASE SEVERITY SCORES  
In all studies, severe sepsis was defined according to the recommendation by the 
American College of Chest Physicians/ Society of Critical Care Medicine Consensus 
Committee: the patients had to have a suspected or confirmed infection with organ 
dysfunction. Furthermore, at least two or more criteria of SIRS had to be fulfilled.40 
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Acute Physiology and Chronic Health Evaluation II (APACHE) score and Simplified 
Acute Physiology Score II (SAPS II) were based on the first 24-hour clinical data and 
chronic health status.271,272 Sequential Organ Failure Assessment (SOFA) score was 
calculated daily based on previous 24-hour clinical data.273 In Study III, we reported 
SOFA both with and without points from platelet count.  
Diagnosis of overt DIC was based on daily calculations of a modified ISTH score for 
overt DIC (Studies I, II and III).7,274 The exact cut-off points for blood platelet count 
and plasma fibrinogen were set as suggested. Quick-type plasma PT was replaced 
by Owren-type PT (percentage of remaining activity). The PT cut-off values of 60% 
and 30% were based on clinical practice and were estimated to equal prolonged PT 
in seconds. As the ISTH criteria lacked an exact suggestion for fibrin-related marker 
limits, D-dimer cut-off values were selected according to former local distribution of 
D-dimer in the critically ill. Modified score for overt DIC is presented in Table 9. 
Table 9. Modified score for overt DIC. 
Points: 0 1 2 3 
Platelet count / x109/l ≥100 50-99 <50 - 
Owren-type prothrombin 
time (activity/ %) ≥60 30-60 <30 - 
D-dimer concentration/ 
mg/l ≤2.0 - 2.1-8.0 >8.0 
Fibrinogen/ g/l ≥1.0 <1.0 - - 
 
Acute kidney injury was defined according to the Kidney Disease: Improving Global 
Outcomes (KDIGO) Foundation guidelines128: increase in serum creatinine (SCr) by 
≥26.5 µmol/l within 48 hours, or increase in SCr to ≥1.5 times presumed or known 
baseline within the preceding 7 days, or urine output < 0.5 ml/kg/hour for 6 hours. 
AKI was further staged to three different groups (1-3) based on the magnitude of the 
changes in serum creatinine concentration and urine output depending on which 
criteria yielded a higher stage.  
4.4 CLINICAL DATA COLLECTION 
For Study I, up to two major intensive care diagnoses were recorded in the 
computerized database. Patients were further classified into two groups: those with 
DIC-associated diagnosis and those without. The patients with DIC-associated 
diagnosis were sub-divided into eight diagnostic groups according to ISTH 
suggestion for underlying diagnoses.7 Routine clinical data including daily laboratory 
measurements, medications, fluids and transfusions were recorded in the 
computerized ICU database locally in Helsinki University Hospital ICU in Studies I-
III. In Study IV, patient demographics, underlying diagnoses, pre- and peri-ICU 
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physiological and laboratory data and outcome were collected in the database of the 
Finnish Intensive Care Consortium (Tieto Ltd., Helsinki, Finland). Data on chronic 
illnesses, medications, organ dysfunctions and implementation of RRT were 
recorded in the electronic case report forms. Disease severity scores were 
calculated locally in Studies I-III and based on data collected in the database of the 
Finnish Intensive Care Consortium in Study IV. Mortality was recorded on day 28 
(Studies I-III) or day 90 (Study IV).  
4.5 LABORATORY ANALYSES 
Blood samples were taken by an arterial cannula after discarding approximately 5 ml 
of blood. The samples were taken at admission (I-IV) and daily in the mornings 
thereafter (I, III, IV). Traditional coagulation assays were analysed by the central 
laboratory of Helsinki University Hospital according to their standards (I-III). Tubes 
for the coagulation assays had sodium citrate to a final concentration of 3.8% (I, III) 
or 3.2% (II). Blood samples from healthy controls (II, III) were taken by venepuncture 
with a light tourniquet from the antecubital fossa. Samples for the 
thromboelastometric analyses were stored at room temperature until analysis, which 
occurred within 15 minutes to 4 hours (II). Serum samples for MMP-8 and TIMP-1 
analyses were obtained simultaneously with the other laboratory tests (III), 
centrifuged at 2000 G for 10 minutes, and the supernatants stored at -80°C until 
analysis. Samples for thrombin-antithrombin-complex (TAT) and prothrombin 
fragment 1+2 (F1+2) analyses were stored at -80°C (III). Samples for histone and 
HMGB1 analyses were collected in ethylenediaminetetraacetic acid tubes and 
centrifuged at 2000 G for 15 minutes. Plasma was stored at -80°C until analysis.  
4.5.1 TEM analyses 
Thromboelastometric analyses were performed with ROTEM® (Pentapharm) with 
four parallel measurement channels and a semi-automated pipetting system 
according to the manufacturer’s instructions. Citrated whole blood (300 µl) was 
pipetted into specifically coated plastic cups and recalcified with 20 µl of 0.2 mol/l 
CaCl2. In EXTEM test, coagulation was activated by adding 20 µl of TF-containing 
reagent, and in FIBTEM test, after activation of coagulation with TF, addition of 10 µl 
of cytochalasin D eliminated platelet function. The tests were allowed to run 120 
minutes. We recorded the following ROTEM® parameters: CT, CFT, α-angle, MCF 
and LI60 at 60 minutes. The difference between EXTEM and FIBTEM MCF 
demonstrated platelet contribution.  
4.5.2 MMP-8 ad TIMP-1 analyses  
MMP-8 and TIMP-1 concentrations were analysed in random order and blinded to 
the clinical state. MMP-8 serum concentrations were measured by time-resolved 
immunofluorometric assay by using monoclonal MMP-8-specific antibodies 8708 
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and 8706 (MedixBiochemica, Kauniainen, Finland) for catching and tracing, 
respectively.275 The assay buffer contained 20 mmol/l Tris-HCl, pH 7.5, 0.5 mol/l 
NaCl, 5 mmol/l calcium chloride, 50 µmol/l zinc chloride, 0.5% bovine serum 
albumin, 0.05% sodium azide and 20 mg/l diethylenetriamine penta-acetic acid. 
Samples were diluted in assay buffer and incubated for 1 h, washed and re-
incubated with tracer antibody labelled using Europium chelate. Fluorescence was 
measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).  
TIMP-1 analysis was carried out by using commercially available two-site ELISA 
according to the manufacturer’s instructions (Biotrak ELISA System; Amersham 
Biosciences, Buckinghamshire, UK). The assay recognizes total human TIMP-1: 
free TIMP-1 and MMP-TIMP-1 complexes.  
The levels are reported as ng/ml. Detection limits for MMP-8 and TIMP-1 were 0.032 
ng/ml and 1.25 ng/ml, respectively. The interassay coefficients of variation for MMP-
8 and TIMP-1 are 4.1% and 13.5% (n=12) and intra-assay coefficients of variation 
2.5% and 10.1% (n=12), respectively. 
4.5.3 Histones and HMGB1 
We studied plasma histone-complexed DNA and HMGB1 as uniplicate by 
commercial sandwich-type ELISA kits, Cell Death Detection ELISAPLUS (Roche 
Diagnostics GmbH, Mannheim, Germany) and HMGB1 ELISA (IBL International 
GmbH, Hamburg, Germany). In hcDNA analysis, mouse anti-histone antibody first 
binds to the histone component of the mono- and oligonucleosomes in the sample. 
Second, the DNA component of the nucleosomes is labelled with an anti-DNA 
antibody that can be photometrically determined.276 HMGB1 ELISA methodology is 
essentially similar to that of hcDNA-ELISA. The results of hcDNA are reported as 
relative absorbance units (AU) and HMGB1 results as ng/ml. 
4.6 STATISTICAL METHODS 
The statistical analyses were performed by using SPSS versions 10.1 (I), 15.0 (II) 
and 20.0 (III-IV) (SPSS Inc., Chicago, IL, USA) and BMDP 1.1 for Windows (BMDP 
Statistical Software, Los Angeles, CA, USA) in Study I. ROC analyses in Studies II 
and IV were performed by MedCalc for Windows versions 9.3.8.0 and 14.12.0, 
respectively (MedCalc Software, Mariakerke, Belgium).  
4.6.1 Sample size considerations 
Study I was a retrospective cohort study, which included all patients in the Meilahti 
ICU during a 22-month period. Studies II, III and IV were preliminary in nature. Thus, 
we lacked previous data on thromboelastometry findings, MMP-8 and TIMP-1 
concentrations, and histone-complexed DNA levels measured by the chosen 
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method in severe sepsis-associated coagulation disorders. In Study II, we assessed 
the B-type error by calculating the difference of means with 95% confidence 
intervals (CIs) between the groups. On the basis of the incidence of DIC in our 
previous severe sepsis patients being about 30% (unpublished data from Study I), 
we targeted the patient count to exceed six in the groups of DIC patients (III). In 
Study IV, we analysed hcDNA and HMGB1 from only 225 of a total of 686 severe 
sepsis patients for economical and futility reasons. Time series were obtained from 
49 patients to observe the kinetics of the substances.  
4.6.2 Data presentation 
Data were expressed as numbers with percentage or median with interquartile range 
(IQR) or 95% CI. Normality of the distribution of the data was tested with histograms, 
skewness and Shapiro-Wilk test. 
4.6.3 Comparisons between and within groups 
Data were non-normally distributed, and we chose non-parametric statistical 
methods for all further analyses. Differences in continuous and categorized data 
were compared with Kruskal-Wallis analysis of variance (multiple groups), Mann-
Whitney U test (two groups), Pearson’s Χ2 test and two-tailed Fisher’s exact test as 
appropriate according to the sample size. Changes in MMP-8 and TIMP-1 
concentrations, and hcDNA and HMGB1 during the study period were analysed with 
Friedman’s two-way analysis of variance based on the ranks. The results are 
reported as Chi square with degrees of freedom and p value.  
4.6.4 Spearman’s correlation 
Correlations between MMP-8, TIMP-1, traditional coagulation assays and disease 
severity (III), and plasma hcDNA and HMGB1 levels (IV) were analysed with non-
parametric Spearman’s rank correlation coefficient Rho (rs) with corresponding two-
tailed p value. 
4.6.5 Logistic regression analysis 
In Study I, step-wise forward multivariable logistic regression analysis assessed the 
independent predictors of 28-day mortality in the original publication. For this 
dissertation, logistic regression analysis was re-performed by inputting a reduced set 
of factors (sex, gender, APACHE II and maximal DIC score) in order to test the 
statistical design of the other studies.60,64 In Study IV, we tested factors having 
independent predictive value on the development of thrombocytopenia, AKI and all-
cause 90-day mortality. The factors having p<0.1 in univariable regression were 
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included in the backward multivariable model. Goodness-of-fit was tested by using 
the Hosmer-Lemeshow test. 
4.6.6 Receiver operating characteristics analysis 
Receiver operating characteristics (ROC) analysis was used in Studies I, II and IV. 
ROC curve illustrates performance of a test by plotting true-positive rate (sensitivity, 
y-axis) against false positive rate (1-specificity, x-axis). The accuracy of the test 
depends on the area under the ROC curve: Area 1.0 represents an ideal test, 
whereas 0.5 is worthless. According to Ray et al.,277 AUC over 0.9 is considered 
excellent, 0.75-0.9 good and 0.5-0.75 poor. One possibility to calculate an ideal cut-
off point for a diagnostic/prognostic test is Youden’s index (sensitivity+specificity-
1).278 For that point, we presented sensitivity, specificity, positive likelihood ratio (IV), 
negative likelihood ratio and positive and negative predictive values (II), as well as 
the confidence intervals (I, II, IV) and the standard errors for the AUCs (I and II). 
Table 10 presents the statistical measures of the performance. 
4.6.7 P value 
A p value of <0.05 was considered significant in all pair-wise comparisons, except in 
Study III, where a level of <0.01 was selected in Spearman’s rank correlation. In all 
multiple comparisons (II-IV), p was corrected by the number of comparisons 
(Bonferroni correction).  
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 Condition: YES Condition: NO  
Test: 
positive 
True positive (TP) 
correctly identified 
False positive (FP) 
incorrectly identified 
(Type I error) 
Positive prediction 
value (PPV) 




False negative (FN) 
incorrectly rejected 
(Type II error) 




= TN/ all with a test 
negative 
 True positive rate 
(TPR) 
sensitivity 
= TP/ all with a condition 
False positive rate 
(FPR) 





 False negative rate 
(FNR) 
= FN/ all with a 
condition 
True negative rate 
(TNR)  
specificity  











5.1 CHARACTERISTICS OF PATIENTS (I-IV) 
The studies comprised a total of 769 patients. Study I included altogether 494 
critically ill patients; 306 patients had a diagnosis known to be associated with DIC. 
Patient characteristics, disease severity scores, diagnostic groups (Study I) and 28-
day mortality are summarized in Table 11 (whole cohort of Study I) and Table 12 
[sub-cohort of Study I (n=306), and all patients of Studies II and III].  
 
Table 11. Patient characteristics, disease severity scores, 28-day mortality and 
diagnostic groups of all patients in Study I. The 28-day mortality rate is previously 
unpublished in these patient groups. 
!




Age 53 (42-64) 57 (50-68) 
Sex (M/F) 221 (72%) 131 (70%) 
APACHE II 15 (11-20) 12 (9-19) 
SOFA day 1 9 (6-12) 6 (4-8) 
Mortality day 28 70 (23%) 33 (18%) 
   
Diagnostic group:   
Sepsis or severe infection 179 na 
Severe trauma 21 na 
Organ destruction 33 na 
Malignancy 10 na 
Vascular abnormality 46 na 
Severe hepatic failure 7 na 
Toxic/ immunologic reaction 8 na 
Obstetric calamity 2 na 
Post cardiopulmonary resuscitation 
status or cardiac failure 
na 148 
Miscellaneous na 40 
Values are presented as number of patients (%) or median (interquartile range). DIC, 
disseminated intravascular coagulation; APACHE II, Acute Physiology and Chronic Health 




Table 12. Patient characteristics, disease severity scores and 28-day mortality in 
patients with critical illness known to be associated with DIC (subgroup of Study I 
patients) and in all patients with severe sepsis (Studies II and III). Unpublished 
results regarding age and gender of the patients in Study I. 
 
Study I II III 
Diagnosis Any critical illness  
known to associate 
with DIC 
Severe sepsis Severe sepsis 












Age 54 (40-65) 52 (45-63) 44 (39-55) 48 (34-58) 53 (46-64) 56 (47-71) 
Sex (M/F) 151 (72%) 70 (74%) 11 (69%) 7 (58%) 7 (54%) 6 (67%) 
APACHE II 14 (10-18)  18 (13-23) 16 (13-20) 24 (18-27) 17 (13-20) 20 (15-22) 
SOFA Day 1 8 (5-10) 12 (10-14) 9 (7-10) 13 (10-17) 7.5 (6-12) 12 (10-14) 
Mortality  
Day 28 32 (15%) 38 (40%) 0 (0%) 5 (42%) 2 (15%) 4 (44%) 
Values are presented as number of patients (%) or median (interquartile range). DIC, 
disseminated intravascular coagulation; APACHE II, Acute Physiology and Chronic Health 
Evaluation II; SOFA, Sequential Organ Failure Assessment. 
 
 
In Study IV, the whole FINNAKI study cohort included 918 patients with severe 
sepsis. Of these, 232 patients were excluded for the following reasons: 123 patients 
fulfilled the criteria of severe sepsis >24 hours after admission, 69 had chronic renal 
failure or RRT was started before admission, and 40 patients declined to participate. 
Of the remaining 686 patients with severe sepsis diagnosis within 24 hours, we 
studied a cohort of consecutive 225 patients (1.9.2011 - 23.10.2011). 
Thrombocytopenia was diagnosed in 75/225 patients (33%). Patient characteristics, 
admission and organ failure data and 90-day mortality are reported in Table 13.  
In Studies I, II and IV, the patients with coagulopathy, either overt DIC (I, II) or 
thrombocytopenia (IV), had higher APACHE II [p<0.001 (I) and p=0.014 (II)], higher 
SAPS II [p=0.001 (IV)], and higher day 1 SOFA scores [p<0.001 (I) and p=0.001 
(II)]. In Study III, disease severity scores did not differ between groups. Number of 
organ failures and proportion of patients in Study IV are presented in Figure 4.  
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Table 13. Patient characteristics, admission and organ dysfunction data and 90-day 




≥ 100 x109 /l 
n = 150 
Platelets  
< 100 x109 /l 
n = 75 
p 
Age 65 (50-74) 67 (57-77) 0.142 
Gender (male,%) 94 (63%) 52 (69%) 0.323 
Baseline creatinine  
(µmol /litre)  79.5 (66-93) 78.0 (66-93) 0.855 
Septic shock 109 (73%) 67 (89%) 0.004 
RRT 11 (7%) 16 (21%) 0.002 
Length of hospital stay 
(days) 12 (7-23) 15 (8-26) 0.388 
90-day mortality 36 (24%) 29 (39%) 0.022 
Organ failure data    
SAPS II 39 (30-46) 44 (35 – 55) 0.001 
Number of organ failures 
(SOFA stages 3-4) 2 (1-2) 2 (1-3) 0.001 
KDIGO AKI (any stage) 63 (42%) 51 (68%) <0.001 
First day of AKI (day) 1 (0-1) 0 (0-1) 0.680 
Highest KDIGO stage:    
Stage 1 26 (41%) 20 (39%) na 
Stage 2 18 (29%) 10 (20%) na 
Stage 3 19 (30%) 21 (41%) na 
 
Values are presented as number of patients (%) or median (interquartile range). RRT, renal 
replacement therapy; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ 
Failure Assessment; KDIGO, the Kidney Disease: Improving Global Outcomes; AKI, acute 





Figure 4. Number of organ failures (SOFA score points 3 or 4) in patients with 
platelet count above and below 100 x109/l (IV).  
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5.2 ROUTINE BLOOD TESTS IN OVERT DIC (I-III) AND 
THROMBOCYTOPENIA (IV) 
Blood platelet count, plasma PT ratio, D-dimer, fibrinogen, AT, CRP and blood 
lactate results in patients with and without overt DIC (I-III) and thrombocytopenia (IV) 
are summarized in Tables 14 and 15, respectively. Coagulation test results (except 
fibrinogen in Study III) differed between groups (all p’s <0.01). No difference in 
plasma CRP between groups existed in Studies I, III and IV. Lactate level was 
higher in patients with DIC (I) and thrombocytopenia (IV) (p<0.001 for both).  
 
Table 14. Traditional coagulation test results in patients with critical illness known to 
be associated with DIC (subgroup of Study I patients) and in all patients with severe 
sepsis (Studies II and III). 
!
Study I II III 
 Any critical illness  
known to associate 
with DIC 
Severe sepsis Severe sepsis 












































































































na na na na na 
Values are presented as number of patients (%) or median (interquartile range). In Study I, 
coagulation test results refer to the most pathological value of the study period; in studies II 
and III to admission samples. CRP and lactate were analysed at admission. DIC, 
disseminated intravascular coagulation; PT, prothrombin time; AT, antithrombin; CRP, C-





Table 15. Laboratory test results in Study IV. 
 
!Laboratory test results Lowest platelets  >100 x109 /l  
Lowest platelets  
<100 x109 /l 
Platelet count  
first 24 hours (x109 /l) 
230 (166-303) 85 (53-113) 
Platelet count 
lowest (x109 /l) 
181 (140-250) 53 (24-83 
Lactate  
highest; day of admission or <24 
hours prior (mmol/l) 
1.9 (1.2 – 3.3) 4.0 (2.5 – 6.9) 
C-reactive protein (mg/l) 160 (61-271) 128 (53-242) 
 
 
5.3 MODIFIED SCORE FOR DIC IN THE DIAGNOSIS OF DIC (I) 
In Study I, 306 patients had underlying diagnosis known to be associated with DIC. 
Of these, 95 patients fulfilled the criteria for DIC during the study period. The 
incidence of DIC during the study period was 95/494 (19%) in all patients, and 
95/306 (31%) in those with appropriate underlying diagnosis.  
The 28-day mortality was higher (38/95, 40%) in the patients with overt DIC than in 
those without DIC (65/399,16%; p<0.001). In the patients with appropriate 
underlying diagnosis without DIC, 28-day mortality was 32/211 (15%). Figure 5 
demonstrates an increase in 28-day mortality with higher DIC score.  
As different components of DIC score were assessed by ROC curves (Table 16), 
platelet count had excellent, PT ratio and D-dimer good and fibrinogen concentration 
poor ability to discriminate patients with overt DIC. AT discriminated patients well.  
Logistic regression analysis revealed only APACHE II score (p=0.003), day 1 SOFA 
(p=0.003), CRP at admission (p=0.036) and the lowest AT (p=0.004) as 
independent predictors of 28-day mortality. In a re-performed logistic regression 
analysis with a reduced set of variables, only APACHE II score and maximal DIC 
score during the study period independently predicted 28-day mortality (p <0.001 for 




Figure 5. Mortality of critically ill patients and the highest score for overt DIC. 
 
 
Table 16. ROC curve AUCs with 95% confidence intervals for DIC score 
components and antithrombin in predicting overt DIC (Study I).  
! AUC 95% CI 
Platelet count 0.910 0.870-0.950 
PT ratio 0.797 0.743-0.851 
D-dimer 0.846 0.803-0.890 
Fibrinogen 0.690 0.596-0.783 
Antithrombin 0.823 0.772-0.974  




























Score for overt DIC 
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5.4 THROMBOELASTOMETRY IN SEVERE SEPSIS AND DIC (II) 
TEM test results are presented in Table 17. EXTEM and FIBTEM parameters did 
not differ in the patients with severe sepsis without DIC as compared with healthy 
controls. Only EXTEM and FIBTEM MCF had a trend for an elevation, but the 
change was not significant after correction for multiple comparisons and predefined 
level of significance (p=0.042 and p=0.034, respectively). Traditional coagulation 
assays, except for platelet count, showed a simultaneous change towards 
coagulopathy (Table 14).  
In overt DIC, EXTEM CFT was prolonged (p=0.002) and α angle (p=0.003) and 
MCF were decreased (p=0.002) relative to both patients without DIC and healthy 
controls (all p<0.01). FIBTEM MCF was at the level of healthy controls (Table 17). 
Figure 6 demonstrates day 1 EXTEM MCF in different study groups as a box plot.  
Figure 7 demonstrates appearance of TEM curves in healthy controls, and severe 
sepsis patients with and without DIC. In severe sepsis with and without DIC, 
fibrinolysis was inhibited as assessed by LI60 (p=0.01 and p=0.002, respectively). 
No change occurred between patient groups (Table 17). 
ROC curves analyses revealed that EXTEM CFT, α angle and MCF discriminated 
septic patients with and without overt DIC well. None of the parameters was 
significantly superior in pairwise comparison. A combination of either α angle or CFT 
with MCF may have increased specificity. Table 18 demonstrates AUCs, 95% CIs, 
cut-off values, sensitivities, specificities and positive likelihood ratios for day 1 
EXTEM CFT, α angle and MCF.  
 
Figure 6. EXTEM MCF (mm) in severe sepsis patients with and without overt DIC 
and in healthy controls.   
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without overt DIC 
n=16 
Severe sepsis 




EXTEM     
CT 64 (54-73) 72 (49-125) 78 (60-104) 0.318 
CFT 88 (78-102) 73 (67-143) 184 (101-285) §¶ 0.004 * 
MCF 63 (58-64) 68 (60-76) 52 (45-58) §¶ <0.001 * 
α-angle 72 (70-74) 76 (66-78) 58 (46-70) §¶ 0.003 * 
LI60 90 (87-92) 96 (91-98) † 97 (93-98) ¶ 0.006 * 
     
FIBTEM     
CT 63 (60-70) 68 (52-94) 71 (60-87) 0.470 
MCF 15 (13-17) 23 (14-36) 14 (11-21) 0.033 * 
LI60 94 (93-96) 98 (96-98) 97 (95-98) 0.093 
Data are reported as median (interquartile range).  * P < 0.05: all groups, † P < 0.01: severe 
sepsis patients without overt DIC vs. healthy controls; ¶ P < 0.01: severe sepsis patients with 
overt DIC vs. controls; § P < 0.01: severe sepsis patients with vs. without overt DIC. CT, 
clotting time; CFT, clot formation time; MCF, maximal clot firmness; LI60, lysis index at 60 
minutes; DIC, disseminated intravascular coagulation.  
 
Table 18. Receiver operating characteristic curve AUCs with 95% confidence 
intervals, cut-off values and positive likelihood ratios for EXTEM parameters in 
predicting overt DIC. 
!
 CFT α MCF α  + MCF 
AUC 0.815 0.828 0.891  
95% CI 0.624-0.935 0.639-0.943 0.715-0.975  
Cut-off value >74 seconds ≤72º ≤63 mm ≤72º and ≤63 mm 
Sensitivity 100% 100% 100% 100% 
Specificity 56% 56% 69% 75% 
LR+ 2.3 2.3 3.2 4.0 
 
AUC, area under curve; CI, confidence interval; LR+, positive likelihood ratio; CFT, clot 






Figure 7. Characteristic TEM curves for healthy controls, and severe sepsis patients 




5.5 MMP-8 IN SEVERE SEPSIS AND OVERT DIC (III) 
Figure 8 demonstrates MMP-8 serum concentration in study groups during the 
whole study period. MMP-8 was elevated in patients with severe sepsis as 
compared with healthy controls (p<0.001 at each time-point). Patients with overt DIC 
differed from those without DIC only on day 2 [702 (IQR 540-1042) ng/ml vs. 246 
(IQR 58-550) ng/ml, p=0.020]. MMP-8 significantly decreased during the study 
period in both patients with DIC (p<0.001) and those without (p<0.01).  
MMP-8 had a strong correlation with TIMP-1. MMP-8 concentration correlated 
negatively only with platelet count on day 2 [r= -0.626, p=0.003). On day 1, 
correlation with platelet count (r= -0.483, p=0.026) did not reach the predefined level 
of significance. MMP-8 had no correlation with disease severity scores, CRP or 
white blood cell count.  
5.6 TIMP-1 IN SEVERE SEPSIS AND OVERT DIC (III) 
Figure 8 demonstrates TIMP-1 concentrations in different study groups with 
significant p values. TIMP-1 concentration was higher in septic patients than in 
controls (p<0.001). Patients with overt DIC had higher TIMP-1 level on days 1 and 2, 
but not thereafter [day 1: 1034 (IQR 793-1102) ng/ml vs. 542 (449-836) ng/ml, 
p=0.014; and day 2: 788 (601-1074) ng/ml vs. 447 (357-545) ng/ml, p=0.006] as 
compared with those without DIC. In all patients, TIMP-1 levels declined during the 
study period (p<0.001 for those with DIC, p=0.002 for those without DIC).  
TIMP-1 had a negative correlation with platelet count on day 2 (r= -0.641, p=0.002), 
with PT ratio on days 1 and 2 (r= -0.760, p<0.01; r= -0.620, p=0.005) and with PC on 
day 2 (r= -0.586, p=0.008). TIMP-1 correlated positively with D-dimer on day 2 (r= 
0.663, p=0.002). TIMP-1 had a positive correlation with SOFA score on days 1 and 
2 (r= 0.634, p=0.003; r= 0.634, p=0.010).  
Figure 9 presents unpublished results on ROC curve for admission TIMP-1 in 
predicting overt DIC. TIMP-1 discriminated patients with overt DIC from those 
without DIC with an AUC of 0.894 (95% CI 0.775-1.000, p=0.001). Due to small 












Figure 8. MMP-8 (a) and TIMP-1 (b) concentrations in severe sepsis with and 
without overt DIC, and healthy controls. Data presented as medians with 95% 











5.7 HISTONES AND HMGB1 IN SEVERE SEPSIS AND ORGAN 
FAILURE (IV) 
Table 19 summarizes plasma levels of hcDNA and HMGB1 in patients with and 
without thrombocytopenia (defined as platelet count <100 x109/litre) or AKI of any 
KDIGO stage, and in those who died within 90 days. As the patients were divided 
into four groups according to the quartiles of hcDNA level, the relative number of 
patients with AKI increased along with elevating hcDNA level (incidence of AKI was 
43%, 39%, 55% and 66% for quartiles I to IV, respectively, p=0.015). 
Figure 10 demonstrates kinetics of hcDNA and HMGB1 during the study period of 
48 hours. The incidence of AKI (49%), thrombocytopenia (43%), and 90-day 
mortality (18%) did not differ from the whole study cohort (p 0.789, 0.110 and 0.066, 
respectively). HcDNA levels increased in 26/49 (53%), decreased in 22/49 (45%) 
and remained unchanged in 1 patient. HMGB1 concentration increased in 17/49 
(35%), decreased in 27/49 (55%) and remained unchanged in 5/49 patients (10%). 
Direction of a change in hcDNA or HMGB1 did not predict thrombocytopenia or AKI 
of any stage in logistic regression analysis (p>0.05 for all).   
Maximal hcDNA correlated moderately with HMGB1 (rs 0.496, p<0.001), and weakly 
with highest lactate (rs 0.298, p<0.001), maximal SOFA score (rs 0.399, p<0.001) 
and SAPS II (rs 0.203, p=0.002). A weak negative correlation occurred between 
hcDNA and lowest platelet count (rs -0.266, p<0.001).  
Table 20 shows the results from multivariable logistic regression analysis. Higher 
hcDNA, age, lower BMI and lactate were independent predictors of 
thrombocytopenia, whereas HMGB1 had no independent predictive value. HcDNA 
did not independently predict AKI of any severity. HMGB1, however, predicted both 
development of AKI stage 3 and 90-day mortality [1.141 (1.030-1.263), p=0.012]. 
Figure 11 and Table 21 present ROC curves and respective AUCs with 95% CIs, 
sensitivities, specificities and positive likelihood ratios for hcDNA and HMGB1 in 





Table 19. Plasma HcDNA and HMGB1 levels in patients with thrombocytopenia, AKI 
of any stage and adverse outcome.  
!
 hcDNA (AU)  HMGB1 (ng/ml)  




    
Yes (n=75) 0.258 (0.100-0.573) 0.002 1.559 (0.550-4.530) 0.009 
No (n=150) 0.154 (0.073-0.285) 0.984 (0.446-1.837) 
     
AKI of any stage     
Yes (n=114) 0.306 (0.146-0.741) <0.001 1.216 (0.676-3.776) 0.009 
No (n=111) 0.150 (0.0638-0.309) 0.921 (0.371-1.719) 
     
Dead on day 90     
Yes (n=65) 0.250 (0.139-0.718) 0.003 1.389 (0.671-4.734) 0.009 
No (n=160) 0.172 (0.066-0.389) 1.041 (0.421-2.005) 
Data are reported as medians with interquartile ranges and p values. AKI, acute kidney injury; 
hcDNA, histone-complexed DNA; HMGB1, high-mobility group box 1.  
 
Table 20. Independent predictors of thrombocytopenia, AKI of any KDIGO 
stage and AKI KDIGO stage 3.   
! Platelets  
<100x109 /litre 




hcDNA  5.433 (1.989-14.837) ** ns ns 
HMGB1  ns ns 1.099 (1.014-1.191) * 
Age 1.032 (1.009-1.056) ** ns ns 
BMI 0.848 (0.775-0.927) ** ns ns 
Diabetes  ns 2.426 (1.188-4.460) * 3.568 (1.542-8.259) ** 
SAPS II  ns 1.032 (1.003-1.063) * ns 
Lactate  1.189 (1.067-1.324) ** 1.183 (1.040-1.346) * 1.089 (1.007-1.178) * 
  
Values are reported as odds ratios (ORs) with 95% confidence interval (95% CI). SAPS II 
score is assessed without renal components and age. * p <0.05 and ** p<0.01. BMI, body 
mass index; SAPS, Simplified Acute Physiology Score; hcDNA, histone-complexed DNA; 
HMGB1, high-mobility group box 1. 
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10 a) HcDNA levels (AU) at different time-points.  
      
 
10 b) Plasma HMGB1 concentrations (ng/ml) at different time-points.  
 
 
Figure 10. Kinetics of plasma hcDNA and HMGB1 in severe sepsis (a subcohort of 
49 patients including patients with both thrombocytopenia and AKI). No change 
occurred in hcDNA level during the first 48 hours (p=0.660) (Figure 10a). HMGB1 
concentration was higher on admission (p=0.048) (Figure 10b).  
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11 a) Thrombocytopenia  11 b) AKI of any stage 
  
11 c) AKI stage 3 
 
Figure 11. ROC curves for hcDNA and HMGB1 regarding thrombocytopenia (a), 






Table 21. Receiver operating characteristic curve data for predicting AKI of 
any KDIGO stage and thrombocytopenia.  
!









      
hcDNA 0.620 0.553-0.684 >0.244 50.9 73.0 1.88 




      
hcDNA 0.673 0.607-0.734 >0.333 60.0 74.1 2.31 
       
HMGB1 0.742 0.679-0.798 >1.628 66.7 71.9 2.37 
 
Platelets 
<100 x109 /l 
      
hcDNA 0.679 0.614-0.740 >0.172 74.7 56.7 1.72 
HMGB1 0.607 0.540-0.672 >2.167 45.3 77.9  2.05 
 
Cut-off point for hcDNA reported as AU and for HMGB1 as ng/ml. AKI, acute kidney injury; 
hcDNA, histone-complexed DNA; HMGB1, high-mobility group box 1; AUC, area under curve; 






6.1 INCIDENCE OF THROMBOCYTOPENIA AND DIC  
Study I conducted in a multidisciplinary ICU of a tertiary care hospital showed that 
incidence of overt DIC in unselected critically ill patients was 19% and in those with 
appropriate underlying diagnosis 31%. The smaller studies (II and III) included only 
patients with severe sepsis. Expectedly, incidence of DIC was higher, exceeding 
40%.  In Study IV, 33% of the patients developed thrombocytopenia (defined as 
platelet count below 100 x109/litre) during the first 5 days in the ICU.  
Different study populations plausibly explain the differences in DIC incidences. In 
Study I, we did not separately analyse incidence of DIC in patients with severe 
sepsis; the proportion might have been higher in that sub-group. Study IV, in 
contrast to the others, was a multi-centre study, including patients from all 
participating ICUs during the recruitment period. Study IV best reflects the incidence 
of severe sepsis-related coagulation disorders in a mixed population.  
Large multi-centre studies (Finnsepsis study and subpopulation of FINNAKI study 
including all patients with severe sepsis) in Finland have reported concordant 
incidences of severe thrombocytopenia, defined as platelet count <50 x109/litre, to 
range from 14.5% to 22%.43,47 Calculation of DIC score, however, requires 
measurements of platelet count, PT and at least D-dimer, and these tests do not 
belong to the daily routines in all patients. In studies from other countries, the 
incidences of thrombocytopenia vary vastly;31 in two large trials investigating the 
potential role of natural anticoagulants in the treatment of severe sepsis, incidences 
of DIC were (in these selected populations) between 30% and 40%, as defined by 
ISTH score.58,59  
6.2 DIC SCORE IN THE DIAGNOSIS OF OVERT DIC 
Originally, the development of the DIC score arose from a clinical need for a unified 
definition. Easily available traditional coagulation tests were included in the score 
based on previous understanding of their behaviour. Study I demonstrated that of 
the components in the score platelet count, PT and D-dimer predicted DIC well, 
whereas fibrinogen seemed to be useless. None of the patients in the study cohort 
had fibrinogen concentration below 1.0 g/litre. Fibrinogen is an acute phase protein, 
which can be strongly up-regulated in inflammatory diseases.279 Since the original 
suggestion, the meaning of fibrinogen in sepsis-associated DIC has been 
questioned,59,78,85 although a study comparing ISTH and JMWH scores and their 
composition suggested that fibrinogen was not a sensitive, but, instead, a specific 
DIC marker in patients without an underlying inflammatory diagnosis.280 Baboon 
endotoxemia model showed that severity of inflammatory reaction and outcome 
depended on individual ability to compensate a transient drop of fibrinogen. Those 
with good compensatory mechanisms survived.281 In non-ICU DIC originating mainly 
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from haematological malignancies, high fibrinogen was associated with worse 
outcome.78  
Platelet count possessed the best discriminative power compared with the other 
components of the score. This is hardly surprising given that it is well known that 
among the coagulation tests platelet count is a strong predictor of organ dysfunction 
and even outcome.32,36-38 Platelets decrease until day 4-6, after which they start to 
increase.33 
D-dimer or some other fibrin-related marker has a central role in the score. 
Originally, ISTH did not give suggestions for exact cut-off points, and they were 
defined as “moderate increase” and   “strong increase”. D-dimer cut-off limits in 
Study I are higher than those suggested by two other studies, as they were selected 
according to former local distribution of D-dimer values (unpublished data).59,64 Also 
other cut-offs have been suggested.282,283 A large number of assays for D-dimer are 
on the market, and their results vary vastly. The authorities have demanded 
validation of different D-dimer assays, but because of the multitude of the assays 
this seems to be an impossible task. The assay used by our central laboratory 
produces somewhat higher results than the assays on average.284 In practice, ICU 
patients almost uniformly have elevated D-dimer regardless of the underlying 
disease. In Study I, 303 of 306 patients had D-dimer >0.5 mg/l, and if this had been 
used as a lower cut-off limit in this study instead of >2.0 mg/l, altogether 124 (41%) 
instead of 95 (31%) of the 306 patients would have fulfilled the diagnosis of overt 
DIC (unpublished data). Thus, in critically ill patients, diagnosis of DIC is dependent 
mainly on prolonged PT/ reduced PT ratio and a severity of thrombocytopenia, as 
virtually all patients present with elevated D-dimer.  
The original suggestion for a DIC score by ISTH included PT ranges in seconds. In 
Nordic countries, PT is measured by Owren-type method for historic reasons, and 
the results are reported as a PT ratio (percentage).70 In Study I, we modified PT 
ranges by replacing them by percentages of approximately the same levels (60% 
and 30%). Most probably, the majority of studies reporting PT values use the Quick 
method. The use of Owren-type PT and the limits chosen are, however, considered 
justified, as assessment of performance of modified DIC score extends the use of a 
score to the Nordic countries.  
Study I showed that antithrombin had a comparable discriminative ability with D-
dimer and PT tests. The idea of replacing fibrinogen in the score with AT is tempting. 
However, its worldwide availability as a routine test is unclear. Recently, 
antithrombin was shown to correlate well with DIC score and to predict 28-day 
mortality.285 Our study does not attempt to answer the question of whether AT 
behaves similarly in other patient groups outside ICUs or whether it improves the 
performance of the otherwise excellent score for overt DIC.  
Surprisingly, diagnosis of DIC made by modified score did not independently predict 
28-day mortality in the logistic regression model, although mortality rate increased 
with higher score. Other studies have quite congruently demonstrated higher 
mortality with higher scoring286-288 and independent predictive power of DIC 
score.60,64 The results from logistic regression analysis are highly dependent on the 
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imputed factors associated with the endpoint. The other studies have included 
remarkably fewer factors in the final analysis. In Study I, it seems rather obvious that 
when adjusted for disease severity (SOFA and APACHE II scores) the independent 
predictive power of dichotomous DIC diagnosis is eliminated. When the variables 
were chosen concordantly with other studies and dichotomous DIC diagnosis was 
replaced by the ordinal DIC score, modified score independently predicted 28-day 
mortality (unpublished data). This may indicate that DIC diagnosis encompasses an 
overly heterogeneous population of patients with coagulation disturbance, and the 
effect of DIC is emphasized only with a higher score, and thus, more severe 
disturbance.  
6.3 TEM IN SEVERE SEPSIS 
Study II demonstrated that patients with moderate coagulopathy in traditional 
coagulation tests but no overt DIC had no changes in TEM parameters, CT, CFT 
and α-angle relative to healthy controls. Only MCF was close to the upper normal 
limit of the reference range, but this trend did not reach statistical significance. DIC 
patients, however, had longer CFT, greater α-angle and lower MCF than both 
healthy controls and patients without DIC. Evidently, milder changes in global 
coagulation tests often seen in severe sepsis have no effect on whole-blood 
viscoelastic properties. In fact, these patients may be even prone to 
hypercoagulation once the process has sufficiently initiated. Only those with DIC 
exhibit signs of hypocoagulation. Prior to Study II, only a few groups had evaluated 
TEM/TEG in sepsis patients and none in DIC.106,107,289 Since then, several larger 
studies have shown consistent results. Studies using ROTEM® in patients with 
severe sepsis or septic shock demonstrate normocoagulation within reference 
ranges108,110,112,113 and hypofibrinolysis.109,110,112 Interestingly, non-survivors and 
patients with higher SOFA score had reduced MCF and α-angle and prolonged CFT, 
suggesting hypocoagulation.108,114 In addition, patients with overt DIC were 
hypocoagulable relative to those without.110,113 All of these studies support the 
finding of Study II that the group of severe sepsis patients with normocoagulable 
TEM/TEG trace on average includes subgroups prone to hyper- and 
hypocoagulation. Hypocoagulable TEM/TEG, in turn, predicts mortality.102,115,119  
The specific aim of Study II was to assess the applicability of TEM in the diagnosis 
of DIC. EXTEM MCF, CFT and α-angle discriminated ISTH score-defined DIC 
patients well, and the combination of MCF with either CFT or α-angle may further 
increase specificity. Only one other study has addressed this question with 
consistent results: Sharma et al.118 studied a TEM score giving one point for each 
TEM parameter indicating hypocoagulation or hypofibrinolysis. If a patient received 
≥2 TEM points, diagnosis of DIC could be set with a sensitivity of 95% and a 
specificity of 81%.  
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6.4 MMP-8 AND TIMP-1 IN SEVERE SEPSIS-ASSOCIATED DIC 
Supported by several other studies, MMP-8 and TIMP-1 were strongly elevated in 
patients with severe sepsis as compared with healthy controls.214,238,244,245,248-250 Both 
MMP-8 and TIMP-1 levels were highest on days 1 and 2, after which they slowly 
decreased. In patients with DIC, the changes over time in both MMP-8 and TIMP-1 
levels were even more prominent than in patients without DIC. A few other studies 
have demonstrated essentially similar kinetics of MMP-8238,247,250 and TIMP-1249 in 
severe sepsis; however, none of them has separately studied patients with 
coagulation disturbance, and therefore, incidence of DIC in their material remains 
unclear.  
Patients with DIC had higher TIMP-1 on days 1 and 2 and higher MMP-8 on day 2 
than patients without DIC. Other clinical studies have not addressed this question in 
their study designs. Interestingly, particularly TIMP-1 had a profound correlation with 
both platelet count and several other coagulation tests, whereas MMP-8 correlated 
with only a severity of thrombocytopenia. Little is known about TIMP-1’s 
independent interactions with coagulation, although similar correlations have been 
reported by two other studies.244,251 In experimental studies, MMP-8 degraded 
TFPI263,265 and fibrinogen,266,290 and its effect on coagulation may be both pro- and 
anticoagulatory. In Study III, MMP-8 had no association with APACHE II or SOFA 
scores. Other studies have reported contradictory findings; whereas two larger 
studies reported an association with organ failure238 and mortality,238,248 two smaller 
studies found no association.214,247 In small studies, like ours, random effect may 
confound the results.  
In the last years, the independent role of TIMP-1 in organ dysfunction and prediction 
of outcome has aroused interest.242,243,245,251,252,291 A variety of inflammatory factors 
can induce expression of TIMP-1,292,293 and elevated levels are probably needed to 
assure efficient inhibition of up-regulated MMPs. Study I supported the 
understanding that TIMP-1 seems to carry more importance in severe sepsis than 
any MMP alone.  
6.5 EXTRACELLULAR HISTONES AND HMGB1 IN SEVERE 
SEPSIS 
The results of Study IV show that systemic nucleosomal hcDNA levels were higher 
in patients with platelet count <100 x109 /litre during the first five days in the ICU as 
compared with patients without thrombocytopenia.  Admission hcDNA had a 
negative correlation with platelet count, and it predicted incidence of 
thrombocytopenia during the study period independently in logistic regression 
model. HcDNA level was stable for the first 48 hours, indicating that if elevated it 
remains high until the later phases of severe sepsis as well.  
Especially free circulating histones have been linked to coagulation disorders in 
experimental and clinical studies.170,188,189,193,206,207 Circulating histones may activate 
and aggregate platelets and induce macro- and microvascular thrombosis at least in 
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experimental circumstances.185,189,294 Recently, a large study with 150 patients with 
deep venous thrombosis (DVT) and 195 controls demonstrated that elevated 
nucleosome levels with signs of neutrophil activation resulted in a 3-fold risk of 
DVT.295  
Studies on nucleosomes interacting with coagulation in intensive care settings are 
scarce. Zeerleder et al.208 could not confirm any correlation between nucleosome 
levels and coagulation in patients with disease severity ranging from fever to SIRS, 
severe sepsis and septic shock (n=69). However, a correlation became evident in a 
sub-group of patients with organ dysfunctions.208 Unfortunately, the authors did not 
report precise data on correlation coefficients or scatterplots.  In children with 
meningococcal sepsis (n=38), admission nucleosome levels had a significant 
correlation with DIC score and several coagulation parameters, including markers of 
enhanced fibrin formation. No data on thrombocytopenia per se were reported.210 A 
small study with 20 patients with severe sepsis used the same hcDNA assay that we 
used in Study IV. HcDNA was reported to correlate with disease severity and 
coagulation parameters.192 Very recently, hcDNA level was shown to be elevated in 
patients with overt DIC, to correlate with DIC score and to predict poor prognosis. 
Unselected critically ill patients presented only a minority of the study population 
(78/199), others having either solid or haematological malignancy, and among the 
patients with overt DIC (53/199) only 20 were critically ill. However, similar findings 
were achieved in both cancer and non-cancer patients.194 
Although circulating nucleosomes seem to be associated with degree of 
coagulopathy, the contribution of nucleosomes to the development of 
thrombocytopenia in severe sepsis remains unclear. As relationships can be 
extremely multi-factorial in complicated illnesses, no straightforward interpretations 
can be drawn from causality based on correlation analyses. However, after 
assessing effects of other confounding factors, multivariable logistic regression 
model revealed an independent role of hcDNA in predicting thrombocytopenia.  
In Study IV, hcDNA levels were associated with disease severity: patients with AKI 
of any stage had higher hcDNA level, as did those who died within 90 days of ICU 
admission.  Previous studies have demonstrated consistent findings.  A recent study 
aiming at validation of nucleosomes in prediction of new-onset sepsis and outcome 
showed that septic patients had higher levels of nucleosomes on admission than 
non-septic controls.209 Admission level also correlated with APACHE II and maximal 
SOFA scores. Quite surprisingly, severity of sepsis did not have an influence on 
nucleosome levels,179 unlike in a previous study by Zeerleder et al.208 An 
experimental study suggested that CRP independently reduces histone toxicity 
against endothelium and histone-induced platelet aggregation.205 The significance of 
this interesting finding in a clinical setting requires further investigations.   Study IV 
confirms earlier findings that nucleosomes are associated with organ dysfunction 
and we extend this relationship to KDIGO-defined AKI.  
Study IV demonstrated that also HMGB1, another nucleus-derived protein, is 
elevated in patients with thrombocytopenia, in AKI patients of any KDIGO stage and 
in 90-day non-survivors. HMGB1 had no value in predicting thrombocytopenia, but 
its significance increased in patients with more severe state of a disease. It 
independently predicted stage 3 AKI and 90-day mortality, which has been the case 
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in some other studies.196,204 However, a previous large multi-centre cohort study on 
incidence and outcome of severe sepsis in Finland could not show any difference in 
HMGB1 levels between survivors and non-survivors.296 In that study, the 
methodology of HMGB1 measurement was different from that in Study IV, serum 
was used instead of plasma, and outcome endpoint was hospital mortality instead of 
90-day mortality. Diversity in the results of different studies questions the 
applicability of HMGB1 as a biomarker.   
Nuclear proteins leaking from injured or apoptotic cells into extracellular space and 
circulation have been said to act as late markers of organ dysfunction and failure. In 
addition to being merely “markers”, they may also cause and facilitate organ 
dysfunction.186 Cytotoxicity is a consequence of interactions between highly cationic 
histones with charged parts of different cell membranes and the endothelium.297 
Thus, deleterious effects of extracellular histones only partly result from their 
interactions with coagulation.  Moreover, histopathological findings are conflicting 
regarding the importance of fibrin depositions and thrombosis in the development of 
organ dysfunction.140,141,147,298 Post-mortem human studies can be confounded by 
severe pre-mortem hypotension and ischaemia, as well as decelerated circulation of 
the organs potentially affecting the coagulation process. Based on Study IV, further 
conclusions about the effect of histones on different organs cannot be made, as we 
were unable to measure local concentrations of nuclear proteins.  
6.6 STRENGTHS AND LIMITATIONS OF THE STUDY 
Some strength and limitations of Studies I-IV should be addressed. First of all, these 
studies provide new information on the incidence of DIC, the applicability of 
diagnostic tools and the complicated pathophysiological process of severe sepsis 
and sepsis-associated coagulation disturbance.   
At the time of publication, Study I was the inaugural study assessing the newly 
established score for overt DIC in a cohort of unselected ICU patients. The study 
was retrospective and based on clinical and laboratory data obtained from 
databases. Thus, no clinical diagnosis of DIC was available that could have served 
as the gold standard. However, the results are very consistent with other later 
studies, except for the role of DIC diagnosis in prediction of mortality. As discussed 
earlier, the statistical method may have influenced the results. Local modification of 
ISTH score for overt DIC can be regarded as a strength instead of a weakness. By 
replacement of PT with PT ratio, also other Nordic countries widely using that score 
can rely on the results. 
Study II was designed as a response to a search for better tools to diagnose a 
degree of sepsis-related coagulation disturbance. However, we were not able to 
compare the results with any specific thrombin activation test. Also the study 
population was too small to allow any interpretations about the clinical significance 
of TEM results in predicting bleeding or thrombotic complications in an ICU setting.  
Patients with severe sepsis may present different phases and severity of a disease 
even at ICU admission. In general, ICU patients, even those with more specifically 
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defined conditions, present a wide spectrum of diseases, chronic illnesses, prior 
medications and so forth. In critical illness research, one must accept this 
contingency and interpret the results while bearing in mind the heterogeneity. In 
smaller studies, heterogeneity of the patients may distort the results, especially if the 
kinetics of the investigated markers is unknown. Study II included only patients with 
severe sepsis at admission, Study III at admission or within 48 hours prior to 
admission and Study IV at admission or during the first 24 hours in the ICU.   In the 
TEM study (II), we reported only admission samples. Kinetic study of MMP-8 and 
TIMP-1 (III) proved that the concentrations were highest at admission and on day 2, 
after which they slowly decreased; kinetics of both hcDNA and HMGB1 were rather 
stable for the first 48 hours. These findings reduce the possible effect of disease 
phase at the beginning of ICU admission.  
Because of the preliminary and descriptive nature of Studies II-IV, expected levels of 
MMP-8, TIMP-1 and hcDNA between study groups were unknown, and thus, proper 
a priori power analyses and sample size calculations could not be performed. In 
Study II, we made post hoc calculations for differences of means with confidence 
intervals to assess the possible effect of Β-type error. Despite small sample sizes 
and wide range of the results, we obtained fairly large differences between the 
medians in DIC and non-DIC patients (1.8-2.9-fold in MMP-8 and TIMP-1 
concentrations). Naturally, these results have to be confirmed in larger studies.  
6.7 METHODOLOGICAL CONSIDERATIONS 
Regarding Study I, the issues concerning laboratory techniques and generalization 
of the results are discussed in Section 6.2.  
Preanalytical factors may affect coagulation test results markedly.299 In critically ill 
patients, blood samples for both clinical and scientific purposes are almost uniformly 
obtained from arterial cannula (Studies I-IV as well), whereas control samples are 
drawn often by venepuncture. A few studies have compared coagulation test results 
of simultaneous samples from arterial and venous lines and found no clinical 
differences. PT, platelet count and fibrinogen tests gave equal results in venous and 
arterial blood.300,301 In venous blood, D-dimer was slightly elevated (0.03 mg/l) and 
AT decreased (2%). Although the results differed statistically, the finding had no 
clinical significance.301 Comparison of TEM/TEG parameters showed that no 
clinically significant difference existed between arterial and venous samples.301,302  
Automation and better standardization of TEM have overcome many earlier 
concerns regarding reliability. Still, however, ICU or operation room personnel 
instead of a hospital laboratory perform the tests, which may reduce the 
reproducibility. Also many patient-related factors may affect the results. In Study II, 
we excluded all those who had received prior anticoagulant therapy within one week 
or those with active bleeding. Due to partly different methodologies and activating 
reagents in TEM and TEG, comparability of the results is questionable.303,304 Briefly, 
a panel of four TEM analyses seems to distinguish different types of coagulopathies 
better that kaolin-induced TEG-analysis alone.305 This must be kept in mind also 
when assessing sepsis studies with either TEM or TEG and divergent findings.  
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In Study III, a central research laboratory with extensive knowledge and experience 
with the methods in question performed the MMP-8 and TIMP-1 analyses. 
Measurements were made from serum samples, which have been criticized for 
yielding inappropriately high concentrations of MMPs and TIMPs.306 No other 
studies on MMP-8 and TIMP-1 in patients with DIC exist; however, two large studies 
on severe sepsis patients have confirmed the acquired TIMP-1 level.244,251 Study III 
compares MMP-8 and TIMP-1 levels within a single study, avoiding generalizations. 
A larger study with more stable and comparable citrated plasma samples is needed.   
In Study IV, histones were measured as hcDNA, giving a relative level of both mono- 
and oligonucleosomal fragments. Other studies using the same assay have reported 
either relative values comparable or higher than ours depending on study 
population190,209,276 or have divided their data into “low” vs. “high hcDNA” sub-
populations for further analyses.191,192 So far, the method lacks clinical validation, 
and no reference range for an “acceptable” level of circulating nucleosomes exists. 
This method does not distinguish the origin of nucleosomes or give information 
about their biological activity.  
In Study IV, HMGB1 was analysed from plasma samples that give essentially lower 
median values than the corresponding serum samples according to a recent 
methodological study (mean recovery of 27%, with a range of 14-32%).307 HMGB1 
stability after centrifugation was, however, good, and repeated freeze-thaw cycles 
did not affect the HMGB1 concentration. Our samples were centrifuged immediately 
after obtaining the sample, frozen to -70°C and thawed only for the final analysis.  
6.8 ETHICAL CONSIDERATIONS 
All studies were performed according to the Declaration of Helsinki, and the Helsinki 
University Hospital Ethics Committee of the Department of Surgery approved the 
study protocols. In Study I, need for an informed consent was waived due to the 
retrospective nature of the study. In Studies II-IV, patients or their next-of-kin gave 
written informed consents; in Study IV also a delayed consent was acceptable.  
None of the study designs caused disproportionate inconvenience to the patients, 
and blood sample volumes obtained were clinically insignificant to patients’ health. 
The study protocols did not affect routine patient care in any way despite 
supplementary blood sampling.  
6.9 CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
Research in the field of coagulation disorders in severe sepsis has come to the end 
of an era. Recent years have clearly demonstrated that coagulation is not a separate 
‘island’ among the other systems, and a close interaction between inflammatory 
mechanisms, overall homeostasis of the cells and coagulation predominate during 
all phases of severe infection. More interest is focused on severe sepsis-associated 
loss of cellular homeostasis causing an inability to maintain normal functions and 
cell-cell interactions, which may lead to organ failure.308 Although the details of 
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cellular dysfunction are beyond the scope of this thesis, several confluences with 
coagulation disturbance should be mentioned.  
Taking into account the multifactorial nature and extreme complexity of severe 
sepsis, it is hardly surprising that large multi-centre trials investigating the usability 
and treatment effect of recombinant anticoagulants AT, aPC and TFPI failed to show 
any benefit in reducing mortality in a heterogeneous patient groups with severe 
sepsis syndrome.309,22,160 Interestingly, later subgroup analyses have demonstrated 
that in more precisely defined subgroups, mostly those with disturbed coagulation 
and high risk of mortality, the treatments may have proven efficient.58,59 According to 
a recent consensus recommendation of ISTH, none of the treatments despite 
routine thromboprophylaxis have been strongly recommended.89 A large phase III 
trial on the effect of recombinant human soluble thrombomodulin in patients with 
severe sepsis-related DIC is ongoing. Also, promising results from a meta-analysis 
combining the data from all clinical studies on thrombomodulin encourage the 
continued development of treatments that simultaneously target both coagulation 
and inflammation.310,311  
Despite the lack of globally accepted and registered treatment for DIC at the 
moment, it is, however, even more important to learn to recognize patients with 
developing coagulation disorders early, so that these patients can be selected for 
future studies from a large, heterogeneous population of severe sepsis patients. 
Although development of multiple organ failure, with a great certainty, is 
multifactorial in origin, coagulation is shown to be one strong contributor. Therefore, 
one could speculate that those patients with developing organ dysfunction with 
coagulation disorder may benefit from new ‘tailor-made’ therapies most. 
Use of any score (ISTH, JMHW, JAAM)7,87,88 for diagnosing DIC is an obvious 
improvement as compared with older times, when DIC was defined purely on the 
basis of well-known alterations in coagulation tests and clinical picture. In the future, 
however, the scientific community should pursue one globally accepted score for 
DIC instead of several local scoring systems. This study showed that ISTH score for 
overt DIC with local modification found those patients with higher morbidity and 28-
day mortality. Fibrinogen had no value in DIC diagnosis in our patients, although in 
some other patient group it may have had more importance.  Implication of AT either 
in the score or as a separate indicator of DIC is challenging, as its availability may 
be limited.  
Since the original suggestion in 2001, Scientific and Standardization Committee has 
strongly encouraged the evaluation of new diagnostic tools, preferably based on 
easily accessible point-of-care methods. This study showed that TEM has a 
potential in the early and definite diagnosis of overt DIC. However, before 
introducing TEM in clinical practice in assessing degree of coagulopathy in patients 
with severe sepsis, several shortcomings must be addressed. Most importantly, 
results from two commercial assays using different methodologies and reagents 
need standardization. Second, instead of local adaptations, widely accepted and 
unified definitions of hypo- and hypercoagulation are needed. Third, as the 
methodology requires trained and committed personnel, it must be decided whether 
TEM will be integrated as part of the haematological laboratory or whether it will 
remain a pure point-of-care method close to the patient. The TEM/TEG traces also 
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require validation regarding critically ill patients’ risk of bleeding and thrombosis. An 
intriguing perspective is that one could use TEM as a tool for assessing the need for 
transfusions and/or more efficient antithrombotic prophylaxis patient-wise. Instead of 
being an all-encompassing method for predicting outcome of large heterogeneous 
patient groups, TEM should be studied is better-restricted sub-groups, in which its 
advantages could be better achievable. 
Neither traditional coagulation assays nor TEM/TEG respond sufficiently to the 
question of whether platelets function normally. For example, impaired platelet 
function measured by impedance aggregometry is associated with poor prognosis in 
severe sepsis.312 Platelet function in disseminated intravascular coagulation requires 
further research, as only a few studies have addressed this question.110  
This study provided new data on MMP-8 and TIMP-1 levels in severe sepsis-
associated DIC. Whether these changes are dependent on only disease severity or 
inflammatory factors or whether they have a real role in coagulation remain to be 
investigated in larger studies. Especially TIMP-1 is interesting. It seems to have an 
independent role in inflammatory states, however it is unknown whether these 
changes are compensatory or detrimental per se. Unpublished findings on the power 
of TIMP-1 in the diagnosis of DIC demand further studies. Also, due to uncertainty of 
comparability of plasma and serum-based studies, these findings concerning a role 
of TIMP-1 in DIC must be confirmed and validated with plasma samples in other 
patient populations and geographical areas. 
Pathophysiology of the development of organ dysfunction and failure in severe 
sepsis is at least as challenging as the multiple cellular interactions in severe sepsis, 
in general. This study provided new information on circulating nuclear proteins and 
their association with thrombocytopenia and organ dysfunction, with special 
reference to AKI defined by new KDIGO criteria. Release of nuclear proteins has 
been suggested as a major contributor of organ dysfunction and failure in sepsis, 
although these findings are mainly based on experimental data. In humans, data on 
local effects of nuclear proteins on development of organ dysfunction are lacking. 
Targeting both histones and HMGB1 with inhibitors in animal studies has proved 
very effective in preventing organ dysfunction.313-317 These findings provide 
interesting future perspectives in developing new strategies in treatment of severe 
sepsis in humans. Especially being ‘late-mediators’ widens the time frame for 
treatment from the earliest moments of the disease to the later phases.  
Critically ill patients form a heterogeneous group with several disease entities, 
different backgrounds and prior health states. Unique features of different subgroups 
of ICU patients prone to coagulation disturbances warrant further investigations. 
One very interesting subgroup with high frequency of coagulation abnormalities, 
often quite profuse need for blood products, severely disturbed permeability, and 
organ dysfunction, is patients with severe burn injuries. In these patients, 
interactions between coagulation and organ dysfunction are particularly poorly 
known.  
In conclusion, DIC is an ultimate end-point of disturbed coagulation in the critically ill. 
Tools for earlier recognition of the patients with potential to develop severe 
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coagulation disorder are needed. The diagnostic repertoire of DIC can be 







The following conclusions can be drawn on the basis of this study:   
 
1. The incidence of overt DIC is 31% in unselected ICU patients, as 
assessed by modified score for overt DIC. Of the components in the 
score, platelets discriminated patients with DIC excellently and PT ratio 
and D-dimer well, while fibrinogen proved useless. AT possesses 
comparable discriminative power as PT and D-dimer. Diagnosis of DIC 
based on modified score was not an independent predictor of 28-day 
mortality. 
2. ROTEM® analysis revealed that severe sepsis patients with DIC were 
hypocoagulable, whereas those without DIC were prone to mild 
hypercoagulation. Traditional coagulation assays, simultaneously, 
demonstrated worsening coagulopathy. EXTEM MCF, CFT and α-angle 
discriminated patients with DIC well. 
3. MMP-8 and TIMP-1 were strongly elevated in patients with severe 
sepsis. In DIC, TIMP-1 was higher on days 1 and 2, and MMP-8 on day 
2, as compared with those sepsis patients without DIC. Especially 
TIMP-1 had a good correlation with coagulation tests and disease 
severity scores. 
4. Systemic hcDNA and HMGB1 levels were elevated in patients with 
thrombocytopenia, in AKI patients of any KDIGO stage and in patients 
who died within 90 days. HcDNA correlated with platelet count and 
disease severity scores and was an independent predictor of 
thrombocytopenia. HMGB1 independently predicted AKI stage 3 and 
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